

Chapter 2

Recent Advances in Tumor Targeting Approaches

Kaushik Thanki, Varun Kushwah, and Sanyog Jain

Abbreviations

17 AAG	17-Allylamino-17-Demethoxygeldanamycin
17-DMAG	17-dimethylaminoethylamine-17-demethoxy-geldanamycin
ADCC	Antibody dependent cellular cytotoxicity
ADEPT	Antibody directed enzyme prodrug therapy
ANA	Monoclonal antinuclear autoantibody
ASM	Acid sphingomyelinase
ATP	Adenosine triphosphate
BCS	Biopharmaceutical classification system
BET	Bromodomain and extra-terminal
BP	Binding protein
BRCA	Breast cancer gene
CDC	Complement-activation dependent cytotoxicity
CDKs	Cyclin dependent kinases
CNS	Central nervous system
CTLA	Cytotoxic T-lymphocyte antigen
dgRTA	Deglycosylated ricin A chain
DMXAA	5,6-Dimethylxanthenone-4-acetic acid
DNA	Deoxy ribose nucleic acid
DOTA	d-Tyr-d-Lys(HSG)-d-Glu-d-Lys(HSG)-NH ₂
EBRT	External-beam radiation therapy
ECM	Extracellular matrix
EPCs	Endothelial precursor cells

K. Thanki • V. Kushwah • S. Jain (✉)

Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Mohali, Punjab, India
e-mail: sanyogjain@niper.ac.in; sanyogjain@rediffmail.com

EZH2	Enhancer of Zeste homolog 2
FAK	Focal adhesion kinase
FDG	2-Deoxy-2-(¹⁸ F) fluoro-D-glucose
GMCSF	Granulocyte-macrophage colony-stimulating factor
GRP78	78 kDa glucose-regulated protein
H3K4me3/2	Trimethylation and dimethylation of histone H3 at lysine 4
HAMA	Human anti-mouse antibody
HARA	Human anti-ricin antibody
hCG	Human chorionic gonadotrophin
HDAC	Histone deacetylase
HER2	Human epidermal growth factor receptor 2
HIF	Hypoxia inducible factor
HOP	HSP90 organizing protein
HPMA	N-(2-hydroxy propyl) methacrylamide
HSP	Heat shock proteins
IFP	Interstitial fluid pressure
IL	Interleukin
IMP-288	1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
JAG1	Jagged 1 protein
LECs	Lymphatic endothelial cells
LLC	Lewis lung carcinoma
LTTs	Ligand-targeted therapeutics
mAbs	Monoclonal antibody
MAPK	Mitogen-activated protein kinase
MCT	Monocarboxylate transporters
MMPs	Matrix metalloproteinases
MPS	Macrophagocytosis systems
mTOR	Mechanistic target of rapamycin
Myc	Myelocytomatosis oncogene
p14 ^{ARF}	Alternate reading frame
PI-3	Phosphoinositide 3-kinase
PDEPT	Polymer directed enzyme prodrug therapy
PE	Phosphatidyl ethanolamine
PKB	Protein kinase B
PSMC2	26S protease regulatory subunit 7 gene
pRb	Retinoblastoma tumor suppressor protein
RAIT	Radioimmunotherapy
Rb	Retinoblastoma
RBC	Red blood cell
RES	Reticuloendothelial system
SAR	Structure–activity relationship
STA	3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole
TCMC	2-(4-isothiocyanatobenzyl)-1, 4, 7, 10-tetraaza-1, 4, 7, 10-tetra-(2-carbamonyl methyl)-cyclododecane

TNF	Tumor necrosis factors
TP53/p53	Tumor protein P53
VEGF	Vascular endothelial growth factor
vSMCs	Vascular smooth muscle cells
WHO	World Health Organization

2.1 Introduction

Tremendous technological developments in the field of cancer therapy have been observed in the past few decades to combat the ever-increasing mortality rate and its peculiar pathophysiology, referred to as carcinogenesis. As per WHO records, cancer is a leading cause of death across the globe accounting 8.2 million and 14 million new cases in 2012 with almost twofold rise in next couple of decades [1]. By definition, cancer is referred to as a generic terminology covering over 200 different types of cancers. Crudely, it is a pathophysiological condition in which the normal cells transform into immortal cells that grow without any control, often referred to as carcinogenesis. Principally, persistent tissue injury and/or genetic factors such as mutations, epigenetic and global transcriptome changes contribute to carcinogenesis (Fig. 2.1). Cumulatively, it could be considered as multistep (comprising a variety of genetic alterations), multipath (including various apoptotic and angiogenesis pathways), and multifocal (constitutive of both field carcinogenesis and clonal expansion) [2]. Subsequently these changes lead to distinct tumor




Fig. 2.1 Key contributing factors of carcinogenesis

microenvironment as compared to normal cells. This discriminatory microenvironment and altered pathophysiological signaling pathways have been classically used in the recent drug discovery approaches and set the genesis of molecularly targeted therapies.

Unfortunately, most of the anticancer drugs till time target the DNA or other biologicals actively involved in cell division and thereby control the rapidly dividing cancer cells. However, in the course of that, the normal host tissues are also not spared and nonspecific generalized toxicity is noted which may be severely intense at times and may lead to either early termination of therapy or other secondary complications. The host tissues main targets include rapidly dividing lymphohematopoietic cells, epithelial linings and other mucus secreting regions of gut, hair follicular regions, etc. These complexities lead to low chemotherapeutic index of the anticancer drugs. Secondly, rapid emergence of drug resistance also contributes majorly to the poor cancer chemotherapeutics [3]. Hence, there lies a strong need to develop selective anticancer therapeutics which would principally act to cancer cells without affecting the normal tissues. The materialization of the concept “magic bullets” seems to be mandatory considering the widespread prevalence of cancer.

Tumor targeting is defined as the improving the drug's chemotherapeutic index by (a) preferentially localizing its pharmacological activities at the site of action, (b) recognition and interaction with target cells, and (c) achieving cellular concentrations so as to exhibit therapeutic response [4]. Very often a variety of homing devices are being employed to direct the drug and/or carriers to the particular site of action. Mechanistically, these homing devices are the special molecular signatures that are expressed to a greater extent at the tumor tissues such as folic acid, etc. The principal need for tumor targeting is required due to limited accessibility of drugs to tumor tissues, requirement of high doses, intolerable cytotoxicity, development of multidrug resistance and nonspecific targeting [5]. However, although fascinating, the tumor targeting is often exposed to a variety of barriers mediated by peculiar tumor microenvironment.

2.2 Normal Vs Tumor Vasculature

Classically, there lies a prominent homeostasis among the proangiogenic and antiangiogenic molecules in the normal tissues which are responsible for balanced organization of the blood vessels for meeting the metabolic demands. This system works in tandem with lymphatics for clearance of the cellular by-products. Carcinogenesis leads to imbalances in these systems leading to a variety of alterations. The chaos starts with alterations in the normal vasculature (abnormalities in the functional and structural aspects) leading to diminished nutrients supply and clearance of cellular waste products. Subsequently, compromised basal membrane, disorganized pericyte layer, downregulation of the adhesion molecules and endothelial linings contribute to high permeability of the tumor tissues.

Tumor vessels usually grow abnormally with unusual vessel diameter, lower vascular density and longer tortuous paths for diffusion of molecules. Further, fluctuant flow, poor plasma channels, and arteriolar-venous shunts for efficient RBCs supply are responsible for two types of hypoxic conditions, i.e., chronic due to compromised diffusion and acute due to lower exchanges, ultimately leading to heterogeneous tumor oxygenation supply [6]. Cumulatively, the principal barriers for the conventional chemotherapeutic agents to access the tumor tissues are malformed tumor vasculature which leads to altered vascular permeability, high interstitial pressure, extracellular acidosis, and hypoxia (due to high mitochondrial oxygen consumption) [7].

Secondly, the interstitial space is regarded as one of the important component for maintaining homeostasis in tissues. It is responsible for exchange of primary requirements of cells such as oxygen and nutrients along with clearance of waste products. In combination with hydrostatic pressure and colloidal osmotic pressure, the transcapillary flow maintains the hydraulic conductivity and plasma protein reflection coefficient among the cells and capillaries in the adjacent to the tissues (Fig. 2.2) [8]. Usually, this transcapillary pressure is slightly higher in capillary bed in the order of 1–3 mmHg so as to maintain the flow of solutes and water from capillaries to cells via interstitial spaces. However, in case of tumors interstitial pressure shoots up to 100 mmHg owing to three principal reasons. These include (a) compromised functionalities of the blood vessel and lymphatics, (b) osmotic pressure generated by drainage of solutes from tissues, and (c) high contractile characteristics of tumor tissues [7]. Interestingly, these are essential targets in the current drug discovery strategies for molecularly targeted therapies.

Thirdly, the pH of the tumor microenvironment is usually dropped relatively towards acidic, as evident from the direct measurement by placing sensitive electrodes into the solid tumors [9]. Classically, it has been widely accepted that hydrolysis of ATP via energy deficient pathways and anaerobic conditions leads to formation of acidic lactate moieties within tumor tissues [10]. Warburg studied the greater production of lactate within the tumor tissues as compared to that of normal tissues and was attributed to the respiratory impairment; however, exact biologics of reduction in tumor pH is not yet identified [11]. The recent advances using genetically modified tumor models revealed that existence of non-lactate mediated acidic microenvironments [12]. It further identified that there exists balance among the intracellular and extracellular pH mediated by proton pumps, which actually regulate the overall tumor pH [13]. Additionally, the uncleared cellular waste products also drastically contribute to the acidic tumor microenvironments [14].

2.3 Barriers to Tumor Targeting

The principal barriers associated with tumor targeting comprise peculiar tumor vasculature which principally comprises heterogeneous blood flow and vascular resistance [15]. In the purview of unregulated growth of tumor vasculature and there




Fig. 2.2 Structural differences between normal and tumor tissues that affect interstitial fluid pressure. (a) Normal tissues contain linear blood vessels lined by a smooth layer of endothelial cells with pericytes maintaining the integrity of the vessel on its outside. The extracellular matrix

occurs nonuniform distribution of blood vessels across the tumor leading to patches of very high blood supply to almost negligible supply. This heterogeneity leads to uneven distribution of administered therapeutics often leading to poor therapeutic response. Such altered distribution also usually ends up in partial exposure of drug to the cells, thereby drastically increasing the multiple drug resistance with the tumor cells. Along with these, achievement of therapeutic responses of drug with cancer cells is further challenged by overexpression of efflux transporters, often referred to as ATP binding cassette (ABC) transporters such as P-glycoprotein, multidrug resistance proteins (MRP-1, -2), etc. Most of the anticancer drugs are substrates of such efflux transporters. This piece of information has been exhaustively reviewed by our group previously and is already available in scientific domain hence kept out of scope of this chapter [16]. Subsequently, other factors such as diffusional barrier due to high intercapillary distance, cell density, and extracellular matrix components also pose potential barrier to tumor delivery of therapeutics.

2.4 Conventional Strategies for Tumor Targeting

The principal goals of the targeted drug delivery system is aimed at protection of the drug in concern to the site of action from the metabolic degradation/inactivation during transit, particularity for specific target devoid of any nonspecific interactions with the host tissues and penetration of relevant concentrations of drug within the tumor tissues for therapeutic responses.

In this regard, selective accumulation of the drug at preferred site is also majorly affected by its physicochemical properties. Most of the anticancer drugs fall in the category II/IV of Biopharmaceutical Classification Systems (BCS), thereby posing pharmaceutical problems while water soluble drugs pose problems related to permeability across various biological barriers [16]. Classically to address these concerns, three major approaches could be employed which include (a) subtle structural modifications for improving the physicochemical properties in accordance with structure–activity relationships (SAR), (b) conjugating homing ligands for pre-determined bio-distribution patterns, and (c) involvement of carrier based approaches



Fig. 2.2 (continued) consists of a loose network of collagen and other fibers, and contains a few fibroblasts and macrophages. Lymph vessels are also present in normal tissues. **(b)** Tumor tissues contain defective blood vessels that are leaky and irregularly shaped, with many sac-like formations, dead-ends and highly activated endothelia. Blood flow is therefore inefficient. These blood vessels are also covered by fewer pericytes than in normal tissues, resulting in decreased vessel stability. Furthermore, many tumors lack lymph vessels, so interstitial fluid and soluble proteins are inefficiently removed. The extracellular matrix of tumors contains a much denser network of collagen fibers, which are thicker than in normal tissues. Therefore, the tumor tissue is more rigid than normal loose connective tissue. Tumors also contain an increased number of fibroblasts, which bind to the collagen fibers in an integrin-dependent manner and exert an increased tension between the fibers, as well as an increased number of macrophages and other inflammatory cells; these cells release cytokines and growth factors that act on cells of blood vessels and stroma fibroblasts to increase interstitial fluid pressure. Reproduced from ref. [8]

for targeting the therapeutics at site of action [17]. Alternatively, targeting could be categorized as either passive or active depending upon the approach employed.

2.4.1 *Passive Targeting*

The natural biodistribution pattern of the drug delivery carrier is exploited for its preferential localization in the vicinity of the tumors such as enhanced permeation and retention effects, phagocytosis of particulate carrier by mononuclear phagocytosis systems (MPS) and preferential localization in the organs of reticuloendothelial system (RES). In addition, other typical properties of the tumor microenvironment such as low extracellular pH, relative micro-acidosis, mild hyperthermia, etc. could also be employed for availing passive targeting of therapeutics. However, the targeting potential of such a strategy is relatively low and often associated with partial nonspecific localization of therapeutics in the normal tissues which needs to be considered while employing such therapies.

2.4.1.1 Enhanced Permeation and Retention (EPR) Effect

The EPR effect was first noted three decades ago for the preferential localization of protein macromolecules in the vicinity of the tumor and since then it has been widely explored for the alteration in biodistribution patterns of most of the colloidal drug delivery systems such as liposomes, polymeric nanoparticles, polymer drug conjugates, etc. However, with the advent of the increased research in this field, EPR effect has been regarded as blanket terminology for increased efficacy of any cancer therapeutics. Aggressive studies in this direction suggested EPR effect as complex association of various processes such as angiogenesis, vascular permeability, hemodynamic regulation, genetic heterogeneities among tumors, lymphangiogenesis, and heterogeneous tumor microenvironment [18].

Classically, the cell proliferation leads to formation of solid mass and upon reaching a specific size, cells in the interior starts getting deprived of the nutrients which leads to cell death and release of growth mediators signaling the development of the blood vessels within tumor. However, the formed blood vessels are often leaky owing to absence of basal membrane leading to fenestrations within the size of 200–2,000 nm [19]. The presence of fenestrations results in poor resistance to the extravasation of macromolecules to the tumor microenvironment and contributes to the enhanced permeation part of EPR. Simultaneously, it has also been found that tumor mass is associated with nonuniform lymphatic drainage and experience a huge physical stress owing to rapid growth in the dimensions of the tumor mass [20]. This leads to the severe compromise in the drainage functionality of the vessels and contributes to the retention part of EPR effect [21].

Principally, the EPR effect is mediated by extravasation of the macromolecules from the blood vessels followed by the subsequent movement in the tumor

microenvironment via diffusion and convection. The principal factors affecting EPR effect includes vessel architecture, interstitial fluid composition, extracellular matrix composition, phagocyte infiltration, presence of necrotic domains, factors pertaining to the colloidal carriers such as blood circulation time, particle size, particle shape, surface charge, and surface functionalization, if any, (e.g., stealth characteristics by PEGylation). Exhaustive review on the factors influencing EPR effect and mobility of the colloidal carriers has been recently compiled and hence kept out of the scope of this chapter [18].

2.4.1.2 Surface Engineering of Colloidal Carriers for Stealth Characteristics

The colloidal carriers by virtue of their inherent properties are rapidly taken up by the mononuclear phagocyte system (MPS) via process of opsonization. However, drastic reduction in RES uptake and significant appreciation in the EPR effect of the colloidal carriers can be achieved by surface engineering [22]. Usually, the opsonins interact with the colloidal carriers via forces such as van der Waal's forces, weak electrostatic forces, ionic forces, and hydrophobic/hydrophilic forces. In purview of this, hydrophobic and charged particles are rapidly processed by RES and significant prolongation in the circulation half-life can be achieved by surface functionalizing PEG chains forming "stealth" systems [23].

A variety of natural materials such as dextrans, pullulans, gangliosides, etc. have been employed for proving stealth characteristics to the colloidal carriers. Of note, gangliosides represent the class of glycosphingolipids containing sialic acid and are regarded as integral component of plasma membrane, particularly red blood cells. The derivatives GM1 and GM type III have been exclusively explored for their potential in imparting stealth characteristics and appreciation in circulation half-life, while reduction in uptake by spleen and liver has been noted at numerous instances [24, 25]. Mechanistically, the stealth characteristics are imparted by steric barrier, shielding of anionic charge, and binding with dysopsonins [26].

The synthetic alternative of the natural polymers for imparting "stealthness" includes polyethylene glycol and their derivatives which have been widely explored and are often associated with numerous advantages such as simple anchoring process, biocompatibility, high solubility, stability, ease of availability at relatively inexpensive cost, flexibility in functionalization, etc. [22]. Although fascinating, the PEGylation of colloidal carriers is also associated with a variety of drawbacks such as significantly higher hydrophilicity hinders the efficient hydration of polar head groups of phospholipids leading to poor stability and problems of drug leaching [27], often necessitating higher levels of cholesterol to prevent aggregation and phase separation [28]. Secondly, there have been some instances of immunogenicity by PEGylated colloidal carriers resulting in hypersensitivity reactions [29]. The activation of complement system and induction of anti-PEG antibodies (IgM) has been observed to rapidly clear off the circulating PEGylated colloidal carrier by a mechanism called ABC phenomenon and is highly detrimental on appreciation in

bioavailability, passive targeting, and ultimately efficacy of the system, per se [30]. Further the long term safety of the PEGs is also scarcely established particularly the biological fate. In purview of this, physiological metabolism of PEGs (<400 Da) includes alcohol dehydrogenase mediated oxidation leading to formation of toxic diacid and hydroxyl acid metabolites [31]. On the other hand, the renal clearance cutoff for PEGs is 30–50 kDa, further narrowing the limits for its clinical use [32]. Hence, a series of alternative synthetic derivatives are currently being explored which include vinyl based lipopolymers, polyoxazolines based lipopolymers, poly-amino based lipopolymers, zwitterionic lipopolymers, etc.

2.4.2 Active Targeting

Active targeting refers to the attachment of marker component to the colloidal carrier system which is specifically recognized by the target in concern may it be either from organelle or organ. Usually molecular targets are employed such as overexpression of surface receptors on tumor cells for site specific delivery of therapeutics such as dietary ligands (carbohydrate based, folate, etc.), monoclonal antibodies and their fragments, non-antibody ligands (peptidic ligands), etc. The active targeting could be divided into various levels depending upon extent of penetration, i.e., organ level, cellular level, and subcellular level. However, independent of the target location, the preliminary characteristic of the targeting ligand is its specificity which should be neither upregulated nor downregulated upon exposure to physiological conditions [33]. Concomitantly, the binding affinity of the targeting ligands should also remain unchanged which indirectly is affected by the binding site barrier leading to altered tumor penetration. At times very high binding affinities are required considering the higher mobility of the colloidal carrier systems in the physiological conditions.

2.4.2.1 Albumin Based Targeting

Albumin plays a critical role in maintaining the homeostasis by mobilizing key endogenous hydrophobic molecules. It specially binds via non-covalent interactions and executes the transport of molecules in concern by transcytosis across the endothelial cells into interstitial space. Paclitaxel bound albumin nanoparticle represents the classical example for establishing the potential of albumin based delivery of anticancer drugs [34]. Mechanistically, it binds to the gp60 receptor present at the cell surface and leads to the activation of the caveolin-1 mediated transcytosis which also unintentionally transports some of the unbound plasma constituents [35, 36]. Concomitantly, tumor cells also secrete albumin binding proteins, SPARC, also referred to as BM-40, which are acidic in nature and rich in cysteine, binding to the albumin tagged colloidal carrier systems. Such a system could fruitfully be exploited

for targeting the therapeutics to the brain via adsorptive mediated transcytosis. Cationized albumin significantly increased the uptake of β endorphin in isolated brain endothelial cells as compared to its native form [37]. Furthermore, ~4-fold increase in the cellular uptake of albumin bound paclitaxel by endothelial cells has been noted as compared to the clinical formulation, Taxol® which was completely inhibited upon coadministration with β cyclodextrin, the known inhibitor of gp60 suggestive of the active transport as predominant uptake mechanism for albumin based nanoparticles [38]. The principal advantages associated with albumin based targeting include superior stability over a wide range of pH (4–9) and temperature (10–60 °C), biodegradation, non-immunogenic, and nontoxic. A striking advantage includes its additional cryoprotectant effect which makes the lyophilization of formulation in concern quite easier than other systems in race.

2.4.2.2 Vitamin Based Targeting

The vitamins employed for targeting potential includes folate, vitamin B₁₂, thiamine, and biotin [39]. The principal advantages associated with vitamins, particularly folic acid, includes stability over shelf and physiological conditions, relatively inexpensive, nontoxic, non-immunogenic, endogenous homing ligand, wide flexibility for diverse chemical reactions, and relatively higher overexpression of folate receptors on most of the cancers [40]. It has been noted that folate functionalized colloidal carrier systems are preferably absorbed by receptor mediated endocytosis. Folate functionalized nanoparticles have been widely explored by numerous research groups including ours for its potential in preferentially localizing the therapeutics in the vicinity of the tumor tissues. Our group has developed methotrexate loaded folate functionalized albumin nanoparticles for significantly improving its antitumor efficacy and reducing the toxic side effects by virtue of altered biodistribution pattern to target tumor tissues as evident by pharmacoscintigraphic evaluation [41]. In a separate set of experiments functional magnetite nanoparticles have also been explored for active targeting potential which were found to selectively target and induce apoptosis in folate receptor overexpressing cancer cells, thereby imparting significantly higher anticancer properties as compared to parent drug [42].

Furthermore, folic acid functionalized carbon nanotubes have also been explored to a greater extent to assess its potential for cancer theranostic applications which comprised fluorochrome (Alexa Fluor 488/647), radionuclide (Technitium-^{99m}), tumor-targeting module (folic acid), and anticancer agent (methotrexate) [43]. The developed system exhibited significantly higher internalization within lung cancer cell lines (A549) and breast cancer cell lines (MCF-7) as evident by the lysosomal trafficking and resulting in higher anticancer activity. Subsequently in vivo experiments revealed ~19-fold increase in the tumor localization for the targeted formulation as compared to free drug. Table 2.1 reveals the representative list of formulation approaches employed for improving the tumor delivery of therapeutics using folate as targeting ligand.

Table 2.1 Folate conjugated nanoparticles for improved tumor delivery of therapeutics

Delivery system	Drug	Outcomes	Ref.
Magnetic multi-walled carbon nanotubes	Doxorubicin	Efficient uptake by U87 cells and higher intracellular release of DOX	[44]
HPMA copolymer conjugate	Doxorubicin	Higher apoptosis and greater tumor spheroid inhibition against Hela cells	[45]
High-density lipoprotein nanoparticles	–	Enhanced selectively towards ovarian cancer cells	[46]
Superparamagnetic iron oxide (Fe ₃ O ₄)	Doxorubicin	~2.5-fold higher than that for the non-targeting group.	[47]
Folate-tagged liposomes	Ricin	Significant increase in the cytotoxicity up to 557.7-fold was demonstrated by monensin intercalated folate liposomes	[48]
pH responsive polymeric nanoparticle	Doxorubicin	Increased targeting efficiency of polymeric nanoparticles, resulted in enhanced cellular uptake by 100-fold	[49]
PLGA nanocapsules	Quercetin	Folate modified PLGA nanocapsules showed selective uptake and cytotoxicity to folate expressing Hela cells	[50]
Poly(L-γ-glutamyl glutamine) (PGG) nanoparticle	Docetaxel	Folate targeted PGG nanoparticle system was found to be highly effective against tumor cells and successfully localized in the tumor site	[51]
Polyhedral oligomeric silsesquioxane-F68 hybrid vesicles	Doxorubicin	Significantly enhanced the uptake in Hela and HOS cells	[52]
Polymersome	Doxorubicin	Higher anti-glioma effect compared to the treatments with free doxorubicin	[53]

2.4.2.3 Transferrin Based Targeting

Transferrin receptors are also exclusively overexpressed in most of major types of tumors including lung, lymphomas and breast cancers in the order of ~10-fold [54]. The important feature of employing transferrin as targeting ligand is its capability for enabling the transcytosis across blood brain barrier [55]. Sahoo et al. exhaustively explored the potential of transferrin conjugated paclitaxel loaded nanoparticles for variety types of cancer including breast cancer and prostate cancer [39]. Significantly higher levels of paclitaxel were noted in the case of transferrin conjugated nanoparticles during cell uptake studies as compared to that of free drug and non-targeted formulation counterparts [56]. Furthermore, in separate set of experiments, transferrin conjugated nanoparticles revealed about threefold higher uptake in PC-3 cell lines and concomitantly significant increase in therapeutic efficacy was noted for the developed formulation in in vivo murine model as compared to that of free drug and non-targeted formulations [57]. Table 2.2 represents the representative list of transferrin conjugated nanoparticles employed for improving the tumor delivery of therapeutics.

Table 2.2 Transferrin conjugated nanoparticles for improved tumor delivery of therapeutics

Delivery system	Drug	Outcomes	Ref.
Mesoporous silica nanoparticles	Camptothecin	Enhanced uptake by Panc-1 cancer cells and toxicity of cancer cells as compared to normal cells	[58]
TRAIL (TNF-related apoptosis-inducing ligand) nanoparticles	–	5.2-fold higher tumor accumulation	[59]
Liposomes	Doxorubicin	Significant improvement in survival time	[60]
Pegylated nanoscaled graphene oxide (GO)	Doxorubicin	Enhanced intracellular delivery, efficiency and stronger cytotoxicity	[61]
Lipoplex	Cytosine deaminase	Significant tumor reduction and enhanced apoptosis	[62]
DQAsomes	Paclitaxel	Higher uptake and tumor cytotoxicity	[63]
Polymeric micelles	Curcumin and Paclitaxel	Improved cytotoxic effect against the SK-OV-3 cells	[64]
Polymeric nanoparticles	si-RNA	Marked tumor accumulation	[65]
Selenium nanoparticles	Doxorubicin	Significantly enhanced cellular uptake	[66]

2.4.2.4 Lectin Based Targeting

Lectins represent a class of cyto-adhesive targeting ligands which is moderately recognized by glycans on the glycosylated cell surface proteins and lipids. Most of the cell surface expresses peculiar glycan arrays which can be sensed differentially and hence this could be a viable strategy as regards targeting perspectives [67]. The targeting potential of lectins has been explored in a wide field of applications including gastrointestinal targeting, nasal delivery, pulmonary delivery, buccal cavity, ocular drug delivery, and brain delivery. Of note, targeting of liver targeting has also been quite possible using lectins for delivering drugs and genes. The asialoglycoprotein receptors are specifically overexpressed on liver which recognizes either β -galactose or *N*-acetyl galactosamine residues [68]. Interestingly, this approach could also be employed using polymer drug conjugates wherein drug and galactose residues can be covalently linked to polymer backbone [69]. On similar line of action, asialofetuin tagged liposomes have also been explored to improve the hepatic delivery of hydrophilic molecules [70].

2.4.2.5 Peptide Based Targeting

Peptide based tumor targeting strategy is considered as most promising because relatively higher stability and smaller size of tumor specific peptides. The peptides

employed for tumor targeting could be either monomeric, homodimeric, heterodimeric oligomeric or tetrameric in nature. Cyclic RGD peptide anchored liposomes were previously prepared preferentially targeting anticancer drug 5-fluoro uracil to tumor vasculature. In vitro endothelial cell uptake studies revealed significantly higher uptake of RGD labeled liposomes as compared to non-targeted counterparts leading efficient prevention of spontaneous lung metastasis and angiogenesis[71]. The tumor specific peptides could be broadly categorized into two categories, one targeting tumor cell surface while other targeting tumor vasculature. The cell surface targets could be either lymphomas, myelomas, neuroblastomas, breast cancer, head cancer, neck cancer, prostate cancer, endothelial cells, or human laryngeal carcinomas whereas the tumor vasculature targets could be $\alpha_v\beta_3$, $\alpha_v\beta_5$, aminopeptidases, proteoglycans, gelatinases, and vascular endothelial growth factors [72].

2.4.3 Physical Targeting

A variety of physical approaches have also been explored for their potential to preferentially localize anticancer medicaments in the vicinity of tumors. The physical stimuli for drug targeting may either be endogenous such as pH, temperature, redox potentials, etc., or be exogenous, i.e., employment of external forces such as magnetic, ultrasound, etc. [73]. As discussed earlier, the tumor microenvironment is slightly acidic and exhibits mild hyperthermia which could be specifically exploited as a stimulus for physical targeting. Stimuli responsive colloidal systems have been designed and developed that tend to degrade at acidic pH and/or elevated temperatures. On the other hand, magnet assisted tumor targeting approaches have also widely been explored considering its immense potential. In this particular system, the drug in concern is immobilized on ferromagnetic colloidal carriers and allowed to circulate in body. The external magnetic field is applied at the site of action which localizes the circulating carriers leading to exceptional tumor levels of drugs. Similarly, the circulating colloidal carrier may be accumulated at the desired site of action using ultrasound energy. Significantly higher tumor levels of doxorubicin were noted from polymeric micelles upon imparting external ultrasound as compared to that of free drug counterpart [74]. The driving force for preferential localization herein is the destabilization of colloidal carrier upon exposure of high energy external force.

2.5 Recent Advances in Tumor Targeting Approaches

2.5.1 Molecular Targeted Therapies

Persistent tissue injuries to the cells and/or factors generally tend to dysregulate the well organized signaling systems of cell cycle and ultimately leading to tumorigenesis. Further, understanding of the fact that either a particular site of molecule or




Fig. 2.3 Cell cycle checkpoint pathways

whole molecule itself can play very diverse role in the normal cells and cancer cells, makes the things quite complicated yet interesting. In this regard, molecular targeted therapies are sought and principally include agents which act on aberrant functions and expression of cell cycle involved in the pathophysiology of cancer such as interference with the pathways exclusively expressed in tumor cells. The cell cycle comprises four phases, viz., G₁, S, G₂, and M phase. Depending upon the cell signaling, the cells in G₁ phase determines whether to proceed with S phase, apoptosis, or G₀ phase. Upon entering the S phase, DNA synthesis takes place which is followed by G₂ phase ultimately enabling the cell to enter M phase where cell division occurs and cell cycle continues. Concomitantly, the cell cycle processes are also regulated by a variety of kinases referred to as cyclin dependent kinases (CDKs) [75]. A series of CDKs and CDKs inhibitors have been known which are constantly employed for ensuring correct cell division processes [76]. Some of these CDKs also monitor checkpoints that cover DNA damage, antephase, and spindle assembly (Fig. 2.3).

In contrast, tumorigenesis involves multiple complex set of conditions wherein the genetic aberrations and dysregulation of cell cycle occur. Apart from downregulation of tumor suppressor genes such as TP53, BRCA1, BRCA2, alterations in the cell cycle also contribute equally to tumor progression. A variety of mediators have been known which actually bridge the gap between dysregulation of cell cycle and genomic instability such as telomere crisis [77]. Secondly, downregulation of retinoblastoma tumor suppressor protein (pRb2) is regarded as the hallmark of tumor cells and mediates by overcoming the S-phase checkpoint and is referred to as CDK/p16^{INK4A}/pRb pathway. Thirdly, p53/HDM2/p14^{ARF} pathway is also considered one of the major cell cycle surveillance pathway operated by HDM2 gene amplification or p53 gene alterations [75]. It affects G₁ checkpoint and is sensitive to a variety of stress signals such as DNA damage, hypoxia, etc. Of note, E3 ubiquitin ligase is the key enzyme responsible for p53 ubiquitylation and proteasome inhibition resulting in transcriptional changes and completes negative feedback loop. Inhibition of the CDKs is an important target and is explored to a greater extent. These strategic inhibitors could be designed to compete via inhibition of the ATP binding sites or upregulation of the native CDK inhibitors. Among various

cyclins known till date, cyclin D and E are often found to be overexpressed in a variety of malignancies [78, 79].

In the purview of molecular targeted therapies, the available bioactives could be crudely categorized among three broad generations, viz., first generation comprising ones that act predominantly via DNA damage, synthesis and/or other linked processes such as tubulins, second generation comprising agents that target cancer growth signaling mechanisms such as kinases, etc., and third generation, which is actively updated and is regarded as most recent and under development, comprising agents which act on cellular pathways indirectly related to cancer growth such as chromatin modifiers, protein chaperones, proteasome inhibitors, etc. (Fig. 2.4) [80].

The classical problems associated with first generation anticancer agents include genesis of secondary cancer such as multiple neoplasms in the pediatric patients survived with childhood cancers [81], long terms survivors of patients suffering from testicular carcinomas [82], etc. Furthermore, it also severely affects rapidly proliferating normal cells such as hair follicles, cells of hematopoietic system, gastrointestinal tract lining, and so on. In addition, detrimental effects on post mitotic tissues such as cardiac muscles and that of peripheral nervous systems have also been observed [83, 84].

Second generation molecularly targeted anticancer therapeutics, to some extent addressed the complications associated with classical drugs. Oncogene addiction and non-oncogene addiction targets have been identified which are either direct gene alterations or indirect alterations, respectively [85]. These alterations could be either due to gain- or loss-of-function mutations, amplification and/or overexpression of oncogenes such as MYC, Rb, p53, etc. Recently, it was identified that close to 20 % of kinases play critical role in tumorigenesis[86]. In this regard, Gleevac (imatinib), a potent inhibitor of tyrosine kinase, was the first product approved clinically for chronic myeloid leukemia [87]. Subsequently, a series of drug compounds were approved which includes Lapatinib (HER2 and epidermal growth factor receptor), vemurafenib (B-Raf), vismodegib (Hedgehog signalling pathway), ruxolitinib (Janus kinases), gefitinib (epidermal growth factor receptor), Sunitinib, sorafenib, and pazopanib (multiple tyrosine kinases), and tivantinib (hepatocyte growth factor receptor) [80]. In addition, the monoclonal antibodies, discussed in latter part of this chapter are also considered as second generation therapeutics. The other miscellaneous agents included under this category are non-oncogene addition targets such as checkpoint kinases [88], mTOR[89], etc. Although these agents act predominantly at oncoprotein targets and are less prone to toxic side effects, acquired resistance has been observed quite often with most of the drugs.

Third generation of molecular targeted therapies is further in move considering the complications associated with available drugs which focusses mainly on DNA synthesis, replication, repair, and cell division. These agents include:

2.5.1.1 Agents Acting on Protein Folding and Proteotoxic Stresses

Considering the typical microenvironment in the vicinity of tumor, cancer cells constantly experience a variety of stresses, especially permanent proteotoxic stress




Fig. 2.4 Cellular multicomponent machineries as current and future targets for anticancer drugs. Current targets (shown in *red boxes*) include: DNA replication and integrity; the mitotic apparatus; chromatin; protein chaperones; and the protein degradation apparatus (the proteasome). Drugs that target DNA replication and integrity act via the following mechanisms: by crosslinking nucleobases in DNA and blocking DNA replication; by inhibiting DNA repair; by inserting planar polyaromatic molecules between DNA base pairs and stabilizing the DNA–intercalator–topoisomerase II ternary complex; by interfering with the polymerization of DNA (e.g., via the incorporation of nucleoside analogues); and by inhibiting nucleotide synthesis, typically using antagonists of ribonucleotide reductases or thymidine synthetase. Drugs that target the mitotic apparatus act by binding to the inner portion of microtubules (the “–” end; e.g., taxanes and epothilones), presumably leading to stabilization and enhanced rigidity of the spindle. Vinca alkaloids bind to the “+” end of microtubules—that is, the end that usually elongates the microtubule by adding subunits of α - and β -tubulin—thereby destabilizing the microtubule. Chromatin modification can be targeted by drugs that act on cellular enzyme complexes such as histone deacetylases (HDACs), bromodomain-containing proteins (BRDs) and DNA methyltransferases. Protein chaperones assist in refolding mutated or stress-misfolded proteins. Complexes consist of the heat shock proteins HSP90 and HSP70 (both of which are ATPases), as well as HSP90 organizing protein (HOP; also known as STIP1), multiple co-chaperones, adaptor proteins, the ubiquitin E3 ligase CHIP (carboxy terminus of HSP70 interacting protein) and the associated HDAC6 (a positive regulator and a cytoplasmic deacetylase that keeps HSP90 deacetylated and active). Drugs can inhibit HSP90, HSP70, or HDAC6. Drugs can inhibit different protease activities—e.g., chymotrypsin-like activity, trypsin-like activity, and/or caspase-like activity—within the 26S proteasome to disrupt the protein degradation apparatus. The ubiquitylation machinery and ubiquitin retrieval can also be manipulated by small molecules, providing additional opportunities for interfering with proteasomal degradation. Future targets for third-wave anticancer drugs are illustrated in *blue boxes*. *ASM* Acid sphingomyelinase, *GRP78* 78 kDa glucose-regulated protein. Reproduced from [80]

which is generally caused by the misfolding and aggregation of proteins. The latter effect is predominantly observed in cancer cells owing to molecular crowding of the cellular milieu [90]. Usually such stresses are counterfeited by a group of molecules inclusive of chaperones and protein remodeling factors. Many of these are responsive to heat and hence referred to as heat shock proteins (HSPs). HSPs interact with their client protein with the help of co-chaperones; however, under extremities of cellular stresses owing to oncogene alterations, chaperone pool vanishes quickly and chaos originates. In complementarily reactive oxygen species further exaggerates the situation and lead to even higher proteotoxic stress [91]. Taking HSP90 as potential target, a variety of therapeutics have been designed for molecular targeting of cancer which includes 17-allylamino-17-demethoxygeldanamycin (17 AAG), ganetespib, STA-9090, IPI-493, retaspimycin, tanespimycin, geldanamycin, radicicol, AT-13387, NPV-AUY922, KW-2478, BIIB-021, MPC-3100, NVP-HSP990, PU-H71, etc. [92] (Table 2.3).

2.5.1.2 Proteasome Inhibitors

Ubiquitin-proteasome system is yet another approach to address the proteotoxic stress covering almost 90 % of the total protein clients [93]. Mechanistically, it follows two steps essentially comprising ubiquitin conjugation mediated by a series of enzymes such as E1 (Ub-activating), E2 (Ub conjugating), and E3 (Ub ligating) to yield Lys48 linked proteins which are then processed for proteasomal degradation via 26S proteasome complex (Fig. 2.5). Herein tumor cells, the proteasome functions and its need is always unmet and hence pose a potential target in anticancer therapy. Concomitantly, the PSMC2 gene alterations further adds complexity to the overall situation. The classical proteasome inhibitors were designed to interact with proteasomal components such as 20S core subunit (Bortezomib, carfilzomib, etc.) [94], interference in the deconjugation of ubiquitin and substrates [95], inhibition of ubiquitin specific peptidase-14 [96], allosteric inhibition of E2 enzyme [97], neddylation[98], etc.

2.5.1.3 Targeting Chromatin Modifications

Chromatin is crudely regulated by three categories of enzyme systems, viz., epigenetic writers, epigenetic erasers, and epigenetic readers [99]. The first category includes enzymes which are responsible for adding chemical moieties to histones or DNA such as acetyltransferases, methyltransferases, etc. The second set of enzymes is primarily responsible for deletion of groups and includes deacetylases, demethylases, etc. The third group comprises the protein modules that are responsible for chromatin binding leading to either upregulation or downregulation of transcription processes, e.g., H3K4me3/2-specific histone demethylase. H3K4me3/2 is a ligand specific for plant homeodomain finger (PHD), zinc finger-like domain, with Cys4-His-Cys3 signature motif [100]. The principal chromatin modification targets

Table 2.3 List of Hsp 70 target based drug delivery system for cancer immunotherapy

Hsp 70 inhibitor	Source	Remarks
Geldanamycin (GA)	Natural benzoquinone ansamycin antibiotic	Compete at the ATP-binding site to induce the degradation of Hsp90 via the proteasome machinery of ubiquitin ligase
Radicalol (RD)	Natural macrocyclic lactone antibiotic	Inhibitory effect against tyrosine kinases countered by reducing agents such as dithiothreitol
17-DMAG	Derivatives of GA	Increased water solubility and better oral bioavailability
IPI-504	Hydroquinone derivative of 17-AAG	IPI-504 shows higher water solubility and also high mortality rate
IPI-493 (17-AG)	Metabolite of 17-AAG	Longer circulation time
KF25706	Oxime derivatives of RD	Stable in the presence of dithiothreitol (DTT)
Herbimycin A (HA)	Benzoquinoid ansamycin antibiotic	Tyrosine kinase inhibitor and exhibits severe hepatotoxicity
KW-2478	Non-ansamycin resorcinol derivatives	KW-2478 caused degradation of FGFR3 as well as Hsp90 proteins, i.e., IGF-ig β and c-Raf-1, which resulted in cleavages of PARP and activation of intrinsic apoptotic pathway
NVP-AUY922	Resorcinol derivatives	Evaluated in Phase I/II clinical trial for NSCLC, breast cancer, colorectal cancer, and advanced gastric cancer and visual toxicity, i.e., night blindness and blurred vision, was reported
HSP990	Resorcinol derivatives	Acts via proteasomal degradation of oncogenic client proteins
AT13387	Resorcinol derivatives	Evaluated in Phase II clinical trial for gastrointestinal stromal tumor in combination with imatinib
Gatenespib (STA-9090)	Resorcinol derivatives	Evaluated in multiple clinical trials for both advanced solid Tumors (NSCLC, colorectal, stomach, ocular melanoma, pancreas, prostate, breast) and hematological malignancies
BIIB-021 (CNF2024)	Purine-scaffold based rational drug	Evaluated in phase I clinical trials for advanced solid tumor, B-cell chronic lymphocytic leukemia
SNX-5422/ PF-04929113	Pyrazole containing scaffolds	SNX-5422/PF-04929113 is water-soluble prodrug of SNX-2112/PF-04928473 and is discontinued in Phase I study due to ocular toxicity

include methylation of DNA and a variety of other histone modifications such as acetylation, ubiquitylation, phosphorylation, etc. Two drugs, 5 azacytidine and decitabine represent the pioneer drugs approved for myelodysplastic syndrome. Recent advances in this area of molecular targeted therapeutics include design of novel agents affecting chromatin modifications such as histone deacetylase (HDAC)




Fig. 2.5 Origin of endothelial cells and assembly of the vasculature. Mesodermal cells in the early embryo differentiate into endothelial precursor cells (EPCs, angioblasts) and form aggregates, known as blood islands (*left*). Fusion of blood islands leads to the vasculogenic formation of honeycomb-shaped primary capillary plexi in the yolk sac and embryo itself. Blood circulation is established and primary plexi are remodelled into a hierarchical network of arterioles and arteries (*red*), capillaries (*grey*), and venules and veins (*blue*). The dorsal aorta and cardinal vein are directly formed through the assembly of angioblasts. The vasculogenic incorporation of circulating EPCs into growing blood vessels may contribute to regenerative or pathological neovascularization in the adult. Vascular smooth-muscle cells (vSMCs) are associated with arteries and veins, whereas capillaries are covered by pericytes (*yellow*). The first lymphatic endothelial cells (LECs) sprout from the embryonic veins, then migrate and form lymphatic sacs. Further steps of lymphangiogenic growth involve sprouting, branching, proliferation, differentiation and remodeling processes. The recruitment of lymphangioblasts from the adjacent mesenchyme has been speculated to be a further source of LECs. Blind-ending lymphatic capillaries (*green*) feed into collecting vessels and ducts. These larger lymphatics are sparsely covered by SMCs (*purple*) and contain valves that prevent backflow. Reproduced from [108]

inhibitors, bromodomain and extra-terminal (BET) proteins downregulators, EZH2 inhibitors affecting histone methyltransferases, etc. [80].

2.5.2 Tumor Angiogenesis

In routine physiological conditions, the vascular network develops in three phases, viz., vasculogenesis, angiogenesis, and vascular remodeling. The first step comprises migration of angioblasts to the desired site followed by differentiation into endothelial cells and subsequent formation of initial vascular plexus [101]. The primary

vascular plexus then undergoes angiogenesis either sprouting or non-sprouting in the presence of various endothelial growth factors and is subjected to remodeling (Fig. 2.5) [102]. Classical long held view on the tumor angiogenesis was restricted to the fact that blood vessels in the tumor microenvironment grow only from the preexisting vessels. However, the recent advances in the field of vascular pharmacology revealed that vasculogenesis contributes majorly in tumor progression and share of endothelial cells derived from endothelial progenitor cells goes shoots beyond 40 % [103]. In purview of this, a variety of factors drives angiogenesis and includes vascular endothelial growth factors (VEGFs), fibroblast growth factors, angiopoietins, netrins, semaphorins (class 3), SLIT proteins, JAG1, DLL4, ephrins, etc. The process of neovascularization is of utmost importance and starts as early as embryogenesis. However, angiogenesis has also been classically associated with a list of pathological conditions including cancer. Although the developmental and pathological angiogenesis operates on similar line of action, the major difference among both is that the latter remains unresolved and principally driven by pathological condition to address the unmet demands of nutrients and oxygen for cells in concern [104].

Crudely, angiogenesis is initiated in tumor upon reaching the size 1–2 mm and is typically coordinated by the hypoxic microenvironment of the tumor. Hypoxia inducible factors (HIFs), heterodimeric transcription factors, direct the expression of VEGF-A for angiogenic sequences [105]. Interestingly, since a series of physiological mediators are required for developing a fully functional vascular system, mere overexpression of VEGF renders aberrantly formed vessels that are often tortuous, fragile, pericyte deficient and leakier to raise the interstitial hypertension and often poor delivery of therapeutics to tumors [106]. Yet another complexity associated with tumor angiogenesis is *vasculogenic mimicry* which is actually a dedifferentiation program wherein the stem-like cells assist in formation of vascular system [107]. Cumulatively, these factors needs to be considered while employing and designing the antiangiogenesis based cancer chemotherapy.

Angiogenesis is considered as very dynamic process and is often regulated by a variety of indigenous angiogenic inducers and inhibitors. The former category includes principally VEGF-A, matrix metalloproteinases, fibroblast growth factors, placental growth factors, hepatocyte growth factors, etc., whereas the latter comprises thrombospondins, endostatin, angiostatin, and cytokines [109]. In the purview of antiangiogenic therapy, Fig. 2.6 depicts the possible targets for efficient management of tumor angiogenesis[103]. Classically, two approaches have been employed for targeting key regulators, i.e., VEGFs. Physiologically, VEGFs signaling system comprises five targeting ligands, VEGF-A to D and placental growth factor and three receptors, viz., VEGFR1-3 tyrosine kinases. The first approach comprises the use of antibodies for VEGF or its receptors and a series of drugs have already been approved clinically such as Bevacizumab (humanized variant, VEGF) and some others are under investigation such as VEGF-Trap_{R1R2}. However, the use of such antibodies is associated with side effects, pharmacoeconomic complications, etc. and hence second approach of VEGF receptor kinases inhibitor could also be sought for. Sorafenib was the pioneer candidate in this category to be




Fig. 2.6 Targeting tumor vasculature to inhibit angiogenesis. (a) Inhibition of binding to pro-angiogenic receptors and/or altering the interaction of angiogenic factors with co-receptors. (b) Penetration into the cells followed by binding with tyrosine kinase receptors (c) Direct activation of receptors, e.g., thrombospondin peptide mimetics (d) Extracellular matrix receptors, e.g., $\alpha\beta3$ integrins. (e) Nonspecific inhibitors of proliferation

approved clinically and was followed by sunitinib, pazopanib, axitinib, etc. Interestingly, significantly higher therapeutic efficacy was noted upon combination of first approach with conventional chemotherapeutics which could be attributed to the *vascular normalization* capabilities of monoclonal antibodies leading to increased delivery of anticancer drugs to tumors. Bevacizumab when combined with irinotecan, fluorouracil, and leucovorin, improved therapeutic efficacy against metastatic colorectal cancer [110]. On similar line of action, combination of aflibercept with fluorouracil, leucovorin, and irinotecan drastically improves the survival in patients with metastatic colorectal cancer [111]. In contrast the actives in the second approach usually work best as single agent and the reasons for discrepancy is in part attributed to the tumor stromal architecture, intrinsic sensitivity, and resistance [112]; however, exact mechanisms are still under investigation [113].

Secondly, thrombospondin-1 represents the naturally occurring secretory angiogenic inhibitors and is principally responsible for organization of the perivascular matrix, endothelial cell adhesion and other process to counterfeit angiogenesis[114]. Numerous therapies have been employed for upregulation of thrombospondins such as metronomic dosing of antiangiogenic agents [115]. Cyclophosphamide has been found to upregulate circulating TSP-1 and not TSP-2 [116]. Notably, said approach

is also reported to sensitize the endothelial cells for TSP induced apoptosis mediated by Fas receptor overexpression [117]. In separate set of experiments, polymer implants containing TSP-2 overexpressed fibroblasts significantly increased therapeutic efficacy in the ovarian carcinoma and drastically higher levels of circulating TSP-2 were noted even after 5 weeks [118].

Thirdly, matrix metalloproteinases (MMPs) are the class of proteolytic enzymes primarily involved in the degradation of extracellular matrix and are part of well coordinated system of growth factors, inflammatory mediators and cell receptors [119]. These macromolecules are important for a variety of physiological functions including angiogenesis and hence, also explored as potential target in design antiangiogenic therapeutics [120]. Although dedicated MMPs inhibitors (MMPI) have not been successfully clinically, research is at advance stages to identify the specific properties which could be sought for rationalized development of MMPI leads.

Further, apart from VEGF based antiangiogenics which primarily block neovascularization, vascular disrupting agents represents a class of bioactives that selectively destroys the already formed tumor vessels by targeting dysmorphic endothelial cells [121]. Combretastatin A4 phosphate is a potent naturally occurring tubulin inhibitor and leads to vascular collapse and shut down of developed vessels and thus impart tumor regression [122]. Mechanistically, these are also reported to interfere with the functions of cadherins, thereby resulting in tumor necrosis. The other vascular disrupting agents include 5,6-dimethylxanthene-4-acetic acid (DMXAA) that tends to increase nitric oxide, serotonin and tumor necrosis factor- α [123]; TZT-1027: dolastatin-10 analog; ZD6126: interferes with microtubules, Exherin®: cyclic pentapeptide; AVE8062A, ASA404, and MN-029.

2.5.3 Cancer Immunotherapy

The cancer immunotherapy seems to have a great potential in terms of clinical cancer therapy considering the remarkable progress in the field of molecular identifications of tumor antigens and increased understanding of various immunoregulatory pathways operative in the tumor microenvironment [124]. It is now well established that the tumor cells pose antigenicity and can be recognized by a variety of immune cells. Recently, the implementation of the shared tumor antigens has been largely replaced with the neoantigens that are generated by point mutations of genes specific to particular types of tumors. This has obvious advantage of improving the antitumor efficacy of the T cells by reducing the nonspecific interactions with that of normal host tissues and increasing the avidity of interactions among antigenic peptide and MHC molecule [125]. Exosome sequencing has been recently employed for defining the mutant antigens for a variety of cancers [126]. Furthermore, more than 20 antibodies are already approved for a series of disease conditions and a large number of them are under exhaustive investigation. Principally, these act through antibody dependent cellular cytotoxicity (ADCC) and complement-activation dependent cytotoxicity (CDC) for imparting cytotoxicity




Fig. 2.7 Strategies for immunotherapy of cancer

and play a crucial role in efficient management of a variety of cancers [127]. In contrast to monotherapies, these antibodies are recently explored as adjuvants in drastically improving the therapeutic effectiveness of the conventional chemotherapies. Recently, antibody derived fragments have been explored to a greater extent as compared to that of parent whole antibodies considering the advantages such as manageable small size, relative ease in production, economic factors, and feasibility in antibody engineering for tailor-made applications. Figure 2.7 depicts various types of strategies that are currently employed for cancer immunotherapies [99, 128, 129].

2.5.3.1 Radioimmunotherapy (RAIT)

RAIT or Radioimmunoconjugates refer to the macromolecular entities where monoclonal antibodies (mAbs) are covalently attached to high linear energy transfer (LET) radionuclides. The radionuclides could either be alpha emitters such as ^{213}Bi , ^{211}At , ^{223}Ra , ^{149}Tb , ^{225}Ac , ^{227}Th , ^{230}U or beta emitters such as ^{131}I , ^{90}Y , ^{60}Co , $^{99\text{m}}\text{Tc}$ capable of damaging DNA either by strand breakage or by other effects ultimately resulting in cell death. Concomitantly, the antibodies itself could also be detrimental to the cancerous cells by altering the signal transduction pathways such as alterations of signaling pathways and depression in gene expression by anti-CD20. Further, the conjugation of antibody with radioimmunoconjugate leads to more *favorable biodistribution* [130]. Considering the huge potential of RAIT, a couple of products (ZevalinTM,




Fig. 2.8 Strategies to improve the therapeutic effectiveness of tumor radioimmunotherapy

Bexxar®, etc.) have already paved their way in clinical segment for treatment of non-Hodgkin lymphomas and many more are under clinical trials.

Since its genesis in early 1950s, the major applicability of RAIT has been hematological malignancies and few decades of research established preferential localization within tumor and subsequent therapeutic potential [131]. Drastic reduction in the bulky masses was noted in patients non-Hodgkin lymphomas treated with ^{131}I Lym-1 monoclonal antibodies [132]. Similar results were also observed with other antibodies such as anti-CD37 [133] and anti-CD20 [134]. The principal factors affecting RAIT includes type of mAbs, nature of radionuclide, and targeted host and tumor. The overall effectiveness of the RAIT further depends on the other factors such as rate and extent of dose administration, tissue penetration and sensitivity, location of target antigens (on tumor or within tumor), bone marrow toxicities, and tumor microenvironment [135]. Figure 2.8 depicts probable strategies that could be employed for improving the efficacy of RAIT whereas Table 2.4 reflects the exhaustive list of radionuclide and monoclonal antibodies employed for efficient management of cancer.

Recently, combination of neoadjuvant radiation therapy and chemotherapy are concomitantly employed for efficient management of cancers. Numerous clinical trials are presently undertaken in the direction of assessing the safety and anti-neoplastic potential of such RAIT, among which majority of trials encompasses combination of external-beam radiation therapy (EBRT), chemotherapeutics, and

Table 2.4 Exhaustive list of radionuclides and monoclonal antibodies employed in combination for efficient management of cancer

Radionuclide	Monoclonal antibody	Outcomes	Ref.
²¹¹ At	A33	Potential for treatment of micrometastases originating from colorectal carcinoma	[138]
²¹³ Bi	Anti-EGFR	Improved therapeutic efficacy of radiation mediated by enhanced DNA damage	[139]
²¹³ Bi	C595	Useful tool for the treatment of micro metastases or minimal residual disease (MRD)	[140]
²¹³ Bi	Herceptin	Improved cell cytotoxicity against BT-474, SK-BR-3, and MDA-231 cell lines	[141]
²¹³ Bi	MTAT	Inhibits lymph node micrometastases by induction of apoptosis	[142]
¹³¹ I	CC49 (scFv) ₂	Provides a promising delivery vehicle for therapeutic applications	[143]
¹²³ I	Tat-peptide	Significant G1–S phase arrest and efficient targeting of nuclear epitopes	[144]
¹³¹ I, ⁸⁸ Y, ¹⁷⁷ Lu, ¹⁸⁶ Re	cG250	Improved stability and specific activity of the radionuclide conjugates	[145]
¹³¹ I, ⁸⁸ Y, ¹⁸⁸ Re	Mu-9 anti-CSAp	Promising results in the treatment of the GW-39 human colonic carcinoma	[146]
¹¹¹ In	Anti-γH2AX	Significant increase in in vitro and in vivo anticancer efficacy	[147]
¹¹¹ In	HuCC49ΔCH2/cCC49	~4-fold appreciation in tumor to blood localization ratio of antibody conjugate	[148]
¹¹¹ In	Mouse IgG (mIgG)	Tumor targeting was found to increase up to 15-fold	[149]
¹¹¹ In	Trastuzumab	Shown potential HER2 specific targeting and radionuclide delivery ability	[150]
¹¹¹ In	U36	Significantly higher uptake in tumor with a favorable biodistribution	[151]
¹¹¹ In and ¹⁷⁷ Lu	HER2/trastuzumab	Improved in vivo biodistribution profiles, tumor uptake and tumor-to-tissue activity	[152]
¹¹¹ In and ⁹⁰ Y	CC49	Significant reduction of extrahematopoietic toxicity	[153]
¹⁷⁷ Lu	chCE7/ ChCE7agl	High and specific accumulation of radioactivity with enhanced antitumor efficacy	[154]

(continued)

Table 2.4 (continued)

Radionuclide	Monoclonal antibody	Outcomes	Ref.
¹⁷⁷ Lu	M-BR96	Increased efficacy without significant increase in toxicity	[155]
²¹² Pb	Trastuzumab	Increased uptake rate in the tumor over a 72-h period with reduced systemic toxicity	[156]
¹⁴⁹ Pm, ¹⁶⁶ Ho, ¹⁷⁷ Lu	CC49	Significant increase in the tumor uptake	[157]
^{99m} Tc	BIWA 1	Increased selectivity and tumor uptake with lower toxicity	[158]
²²⁷ Th	Rituximab	Novel approach for targeted delivery system	[159]
²²⁷ Th	Trastuzumab	Increased cumulative absorbed radiation dose to tumor by fractionation of the dosage	[160]
⁹⁰ Y	HMFG1	Shown potential treatment efficacy at a dose of 18.5 mCi/m ² with reduced toxicity	[161]

immunotherapy [136]. The principal component of the immunotherapy is usually a vascular endothelial growth factor (VEGF)-blocking antibody, whereas preferred chemotherapeutics is a platinum derivative such as cisplatin, oxaliplatin, etc. Table 2.5 lists the clinical trials presently undergoing on cancer RAIT [137].

With the advent of nanotechnology based approaches, the therapeutic effectiveness of the RAIT has been drastically improved. The said approach has been exclusively exploited in a variety of preclinical and clinical conditions and its potential has now been widely accepted. The principal amenities associated with these nanoparticles are their diverse functionalization potentials which help is improving the therapeutic efficacy and reducing the unwanted and toxic side effects to normal tissues. Figure 2.9 depicts the general architecture of these multifunctional nanoparticles and various advantages associated with said approach. In this context, a variety of nanocarriers have been fabricated till date for management of cancer and could broadly be categorized under the banner of either organic or inorganic nanocarriers [162]. Furthermore, employing the radiation chemistry, a radionuclide is conjugated to the antibody to form radionuclide–antibody conjugates which could be either conjugation of peptide ligands and antibodies or tumor targeted antibodies and radioisotopes [163]. The latter is then incorporated into nanoparticles to yield targeted radioisotope labeled nanoparticles [164]. Table 2.6 list various nanocarrier based approaches employed for RAIT. The principal disadvantages with either plain radiation therapies or radio antibody conjugates are longer half lives, higher γ -emissions leading to undesirable side effects, inefficient internalization within lysosomes, mandate chelator requirements which often is associated with poor targeting or nonuniform dosimetry, etc. [165].

Table 2.5 Representative list of clinical trials comprising of radioimmunotherapy

Neoplasms	Phase	Radiation/antibody	Drug
Abdominal	I-III	^{90}Y -HMFG-1, ^{212}Pb -TCMC-Trastuzumab, ^{131}I -8H9	-
Adenocarcinoma	0-II	^{90}Y -m170, ^{90}Y -MN14, ^{18}F -FDG, cetuximab, filgrastim	Paclitaxel, docetaxel, cisplatin
Bronchial	0-II	^{131}I -L19SIP, ^{177}Lu -IMP-288, ^{111}In -IMP-288, antibody TF2, Pre-targeted radioimmunotherapy, ^{90}Y -antiCEA cT84.66, ^{18}F -FDG, cetuximab	Cisplatin, docetaxel
Carcinoma	0-III	^{131}I -di-DTPA, carbon ion boost, ^{177}Lu -IMP-288, ^{111}In -IMP-288, ^{131}I -L19SIP, ^{90}Y -antiCEA cT84.66, ^{90}Y -DOTA anti-CEA M5A, ^{90}Y -HMFG-1, ^{111}In -MN14, antibody TF2, hMN14 (labetuzumab), cetuximab, bevacizumab, filgrastim	Doxorubicin hydrochloride, docetaxel, cisplatin, 5-fluorouracil, irinotecan hydrochloride, leucovorin calcium
CNS	I-II	^{131}I -3 F8, ^{131}I -8H9, ^{131}I -L19SIP	Cisplatin, lomustine, vincristine sulfate
Colorectal	I-II	^{177}Lu -IMP-288, ^{111}In -IMP-288, ^{90}Y -DOTA anti-CEA M5A, ^{90}Y -antiCEA cT84.66, ^{111}In -IMP-205xm734, ^{111}In -MN14, ^{90}Y -MN14, TF2, hMN14 (labetuzumab), filgrastim, bevacizumab	Oxaliplatin, leucovorin calcium, fluorouracil, gemcitabine, floxuridine, irinotecan, hydrochloride
Leukemia	I-II	^{90}Y -Epratuzumab, ^{111}In -LL2 IgG, ^{111}In -MN14, ^{131}I -Anti-B1, ^{131}I -BC8, ^{111}In -ibritumomab tiuxetan, ^{90}Y -ibritumomab tiuxetan, ^{131}I -tositumomab, rituximab, filgrastim, oprelvekin	Busulfan, cyclosporine, cyclophosphamide, etoposide, fludarabine phosphate, methotrexate, mycophenolate mofetil, melphalan, sirolimus, tacrolimus
Liver	I-II	^{90}Y -antiCEA cT84.66, ^{90}Y -DOTA anti-CEA M5A	Gemcitabine hydrochloride, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin
Lymphomas	I-II	^{111}In -ibritumomab tiuxetan, ^{90}Y -ibritumomab tiuxetan, ^{131}I -tositumomab, ^{111}In -LL2 IgG, ^{90}Y -epratuzumab, ^{111}In -Lym-1, ^{90}Y -Lym-1, ^{111}In -MN14, rituximab, filgrastim	Cyclophosphamide, cisplatin, cytarabine, methylprednisolone, fludarabine phosphate, etoposide
Ovarian	I-III	^{212}Pb -TCMC-Trastuzumab, ^{90}Y -HMFG-1, ^{111}In -MN14, ^{90}Y -MN14, filgrastim	—
Prostrate	I	^{117}Lu -J591, ^{90}Y -m170, filgrastim	Cyclosporine, paclitaxel




Fig. 2.9 General architecture of multifunctional nanoparticles and associated principal advantages. Adapted and modified with permission from [166]

2.5.3.2 Immunotoxins

Immunotoxins represent a group of macromolecular species essentially comprising toxin conjugates and targeting antibodies linked via gene fusions, peptide bonds, disulfide bonds, thioether bonds, etc. [180]. Upon successful internalization within target cells, the immunotoxin releases toxin by a variety of mechanisms such as degradation by proteases, reduction of disulfide bonds, or acid hydrolysis (Fig. 2.10). Primarily bacterial toxins such as diphtheria toxins, *Pseudomonas* exotoxin, and plant toxins such as ricin, modeccin, abrin, etc. are employed as toxin conjugates. These are usually proteinaceous in nature and are considered as highly potent, owing to which even limited availability at site of action is sufficient for execution of cellular responses [181]. Once inside the cells, these tend to inhibit the protein synthesis pathways and result in cell cytotoxicity. Although fascinating, the clinical intervention of immunotoxins is a great challenge owing to associated limitations such as poor antigen specificity, lower cytotoxicity potential, nonspecific side effects, immunogenicity, and manufacturing complications. Recently, in the last couple of decades, strategic developments in the field of immunotoxins have been noticed. Started with its genesis from isolation of potential toxins in early 1970s, a variety of immunotoxins have made their way to clinical trials successfully clearing in vitro tissue culture experiments and in vivo preclinical testing. One product, DT-IL2 (denileukin diftitox, Ontak™), has been clinically approved for human use and specifically targets IL-2 receptors [182].

The targeting antibodies could either be whole antibody or small fragments. In the latter case, A chain subunit of the toxin is linked to the monoclonal antibody and are referred to as A chain immunotoxins. A principal advantage associated with such A chain immunotoxins is lower nonspecific side effects in in vivo setting; however, in contrast some significant compromise in overall targeting potential and cell cytotoxicity was noted as compared to whole antibody immunotoxins [183]. The results are indicative of the crucial role of B chain in improving the interactions of immunotoxins with target cells and preferential assistance in entry to cytosol. Furthermore, considering the pharmacokinetic perspectives, the larger the constructs, the longer the circulation half-life. Furthermore, classical to any anticancer

Table 2.6 List of nanocarrier based approaches employed for RAIT

Radionuclide	Nanocarrier approach	Functionalization	Outcomes	Ref.
⁹⁰ Y	Polymerized liposomes	Integrin antagonist; anti-Flk-1 mAb	Significant tumor growth delay in K1735-M2 and CT-26 tumors	[167]
^{99m} Tc	PEGylated liposomes	MIBI	Twofold higher uptake in MCF-7 ras tumor bearing mice	[168]
¹¹¹ In, ⁸⁸ Y	PAMAM dendrimer	Humanized anti-TacIgG (HuTac)	Significant differences in the biodistribution patterns of the saturated and unsaturated dendrimers were noted	[169]
¹¹¹ In	PEGylated PE micelles	2C5	Significantly higher tumor accumulation in murine LLC	[170]
¹¹¹ In	Albumin nanoparticles	RGDGSSV peptide, fibrinogen	Significant retardation in tumor growth and tumor specific reduction blood flow to B16F0 hind limb tumors	[171]
¹¹¹ In	Perfluorocarbon nanoparticles	$\alpha\beta_3$ -integrin binding ^a	Fourfold higher mean tumor activity in Vx-2 tumor bearing rabbits as compared to nontargeted controls	[172]
¹⁸⁸ Re	Liposomes	Doxorubicin	Significant increase in the therapeutic efficacy against C26 murine solid tumor animal model	[173]
¹¹¹ In	Nanocapsules	Polysaccharides	Significant retardation in the clearance rate and preferential biodistribution within lymphatic system	[174]
¹³¹ I	Dextran magnetic nanoparticles	Sc-7269	Significant tumor growth delay and tumor inhibition rate were noted without any compromise in safety profile	[175]
⁹⁰ Y	Apo ferritin	Biotin	Significant pre-targeting capabilities	[176]
^{125m} Te	ZnS nanoparticles	mAb 201B	Significantly higher localization within lungs	[177]
⁶⁴ Cu	Carbon nanotubes	RGD	Significantly higher tumor uptake with minimal renal clearance	[178]
²²⁵ Ac	PEGylated liposomes	PSMA J591 antibody, A10 PSMA aptamer	Significantly higher cytotoxicity against PSMA overexpressing human LNCaP cells, rat Mat-Lu cells and HUVEC cells	[179]

^aPerfluorocarbon nanoparticles bind to $\alpha_v\beta_3$ -integrin receptors




Fig. 2.10 Mechanisms of action of monoclonal antibody (Ab) conjugates. Monoclonal antibodies and their fragments can be conjugated or linked to cytotoxic agents. Chemotherapy and toxin conjugates must be internalized via receptor-mediated endocytosis, whereas internalization is not required for radioisotope conjugates. After internalization, the active cytotoxic component is released and mediates cell death. Ricin-based immunotoxins depurinate ribosomal RNA and inhibit protein synthesis. Pseudomonas (PE)- and diphtheria (DT)-derived immunotoxins ADP ribosylate elongation factor-2 and inhibit protein synthesis. Antibody drug conjugates mediate cytotoxicity by drug-specific actions (e.g., targeting tubulin by maytansin and auristatin, and induction of DNA breaks by calicheamicin). *dgRTA* deglycosylated ricin A chain. Reproduced from ref. [186]

chemotherapy, the potency of immunotoxins could be drastically improved by coadministration with *enhancing agents*. Such improvements in the entry of immunotoxins within the cells could be facilitated by understanding the vesicular entry systems classical to proteins, employing the pathways adapted by natural toxins

during pathological conditions, and exploiting the structure–function relationships of natural toxins in designing the entry systems [184]. Classically, pharmacologically active molecules such as lysosomotropic amines or carboxylic ionophores have also been employed as enhancing agents [185].

Concomitant with high therapeutic potency, there also lie numerous side effects associated with immunotoxins. These includes flu-like syndrome, vascular leak syndrome, infusion related hypersensitive reactions, and transient increase in the levels of hepatic toxicity markers such as transaminases owing to preferential processing of immunotoxins in liver [33]. Furthermore, immunotoxicity can also occur either due to monoclonal antibodies or toxins which could be marginally circumvented by employing antibody alterations or humanization.

Table 2.7 list various immunotoxins employed for management of cancer. Particularly, deglycosylated ricin A (dgA) chains have been particularly explored in a wide array of malignancies considering diminished hepatotoxicity (owing overexpression of mannose receptors in liver) classically observed with anti-B4 blocked ricin [187]. The lateris also associated with significant human anti-mouse antibody (HAMA), anti-ricin (HARA) immune responses and vascular leak syndrome [188]. In purview of this, the particular amino acid sequences in toxins responsible for both therapeutic effects and detrimental side effects have been identified and employed [189, 190]. The reduction in HARA immune responses could be mediated by employing the PEGylated ricin as compared to plain ricin [191]. Interestingly, PEGylation does not affect the inhibition of protein synthesis pathways by ricin.

Notably, immunotoxins usually lacks any bystander effects. However, considering the very therapeutic potency, this property could be fruitfully exploited in combination therapeutic regimen to combat minimal residual diseases, particularly hematological malignancies. Immunotoxins along with RAIT have been successfully employed for treating disseminated human B-cell lymphoma in immunodeficient mice model and curative therapeutic regimen was observed by optimizing the temporal order of administration without any life threatening vascular leak syndrome (Fig. 2.11) [209].

2.5.3.3 Immunocytokines

Immunocytokines represents yet another important type of macromolecular species employed for efficient management of cancer. These are fusion proteins essentially comprise monoclonal antibody and cytokine. Cytokines are referred to as cell signaling molecules responsible for cell–cell communication and mediate a variety of humoral and cellular immune responses to maintain homeostasis [210]. These include interleukins, interferons, chemokines, colony stimulating factors, lymphokines, and tumor necrosis factors, to name a few. Mechanistically, immunocytokines tend to accelerate the compromised tumor immune responses and hence the immunocytokines therapy seems to be most promising as compared to any other immunotherapies (Fig. 2.12). Considering such potential, IL-2 based immunocytokines therapy has been clinically approved for treatment of advanced stages of

Table 2.7 Immunotoxins employed for efficient management of cancer

Toxin conjugate	Monoclonal antibody	Remarks	Ref.
Diphtheria toxin (DT)	Trastuzumab (Herceptin)	Trastuzumab-DT conjugates exhibited significant killing of SK-BR-3 cells	[192]
Diphtheria toxin mutant (CRM9)	Anti-vascular endothelial growth factor (VEGF)	Markedly higher cell cytotoxicity than control groups	[193]
Gelonin	Monoclonal antibody 31 (MOC31)	MOC31-gelonin and 5-aminolevulinic acid (5-ALA) combination induced synergistic cytotoxic effect against the WiDr cells via enhanced photo chemical internalization as a result of protoporphyrin IX (PpIX)	[194]
Granzyme M	Humanized single-chain antibody fragment (scFv) H22	Specific and efficient toxicity upon binding to CD64, an FcγRI receptor overexpressed on activated myeloid cells and leukemic cells	[195]
Listeriolysin O (LLO)	B3	Specific elimination of antigen positive MCF7 cells with up to 80–250-fold less sensitivity towards antigen negative cell lines	[196]
LysPE38QQR (truncated form of Pseudomonas exotoxin)	K1 (murine IgG1)	Exhibits higher toxicity against mesothelin positive A431-K5 cells	[197]
Mutant Pseudomonas exotoxin A (ETA')	anti-EGFR 425(scFv)	Higher binding activity and specificity of towards EGFR-positive pancreatic carcinoma cell line L3.6p1	[198]
Mutant Pseudomonas exotoxin 38 (PE38)	B3	About 12-fold higher cytotoxicity on CRL1739 cell lines	[199]
Pseudomonas exotoxin (PE38)	Mutant MR1(Fv)	Increased affinity and cytotoxic activity	[200]
Pseudomonas exotoxin 38 (PE38)	RFB4	Exhibited fivefold to tenfold increase in activity on various CD22-positive cell lines and up to 50 times more cytotoxic to cells from patients with chronic lymphocytic leukemia and hairy-cell leukemia	[201]
Pseudomonas exotoxin 40, (PE40)	Humanized anti-CEA antibody (hMN14)	hMN14(Fv)-PE40 showed specific growth suppression of CEA expressing cell lines MIP-CEA (high CEA) and LS174T (moderate CEA) with IC _{50s} of 12 ng/mL (0.2 nM) and 69 ng/mL (1.1 nM) respectively with reduced toxicity towards normal tissues	[202]
Pseudomonas exotoxin A	anti-CD22	Remarkable increase in thermal stability and an enhanced resistance to trypsin degradation	[203]

(continued)

Table 2.7 (continued)

Toxin conjugate	Monoclonal antibody	Remarks	Ref.
Pseudomonas exotoxin A ETA	HER2-specific single-chain antibody scFv(FRP5)	scFv(FRP5)-ETA showed specifically higher cytotoxicity towards HER2 positive cell lines LNCaP	[204]
rAbrin	mAb F1G4	Immunotoxin mAb F1G4-rABRa-A, inhibits protein synthesis specifically on cells expressing the gonadotropin releasing hormone receptor and also it exhibited differences in the kinetics of inhibition of protein synthesis, in comparison to abrin, which was attributed to differences in internalization and trafficking of F1G4-rABRa-A within the conjugate	[205]
Recombinant gelonin toxin (rGel)	FGFR3-specific Fv fragments (3C)	3C/rGel fusion showed an significant reduction of IC ₅₀ value up to 200 nmol/L against cells compared with 1, 500 nmol/L for free rGel	[206]
Ricin A	(anti-PSMA) monoclonals (J591, PEQ226.5, and PM2P079.1	Various immunotoxins showed an significant reduction PSMA + cells with IC ₅₀ value in nanomolar range (IC ₅₀ s of 1.6–99 ng/mL) and complete eradication with J591-smpt-nRTA with IC ₅₀ of 0.35–31.7 ng/mL	[207]
Saporin	Trastuzumab (Herceptin) and cetuximab (Erbixux)	Trastuzumab (Herceptin) and cetuximab (Erbixux) were conjugated via cleavable disulfide bonds to the plant derived toxin saporin shown to have overcome the present limitations of therapeutic antibodies with a higher antitumoral efficacy via endosomal/lysosomal release of the toxin moiety	[208]

melanoma and renal carcinoma [211]. In addition, some allied pharmacological activities of cytokines have also been noted such as inhibition of tumor vasculature by tumor necrosis factors [212]. Considering the physiological functions of cytokines as either auto or paracrine factors, pretty high concentrations needs to achieved in the close proximities of site of action, i.e., producing cells. However, the clinical limitations does not permit such high dose administrations systemically [213] and hence the classical approaches includes either direct injection within solid tumor [214] or localized treatment such as isolated limb perfusion of tumor necrosis factor [215]. Unfortunately, the said approaches does not comply in most of the malignancies at the advanced stages and hence the concept of immunocytokines emerged wherein a tumor antibody is attached to the cytokine to achieve preferential higher tumor concentrations and hence drastically reduce toxic side effects to normal tissues. Furthermore, drastic improvements in the pharmacokinetics of cytokines could be achieved by said strategy [210].




Fig. 2.11 Internalization of ligand targeted therapeutics and the "bystander effect." (a) Binding of the ligand-targeted therapeutics (LTTs) to their target epitopes will, in the case of some antibodies, promote receptor-mediated internalization of the LTT and, following release of the therapeutic intracellularly, lead to cytotoxicity (e.g., immunoliposomes and immunotoxins). (b) Binding of LTTs linked to noninternalizing antibodies will result in the LTT remaining attached at the target-cell surface (e.g., ADEPT (antibody-directed enzyme-prodrug therapy)). (c) All the cancer cells will preferably express the target epitope; however, some of the cancer cells might not. Drug that is released into the tumour interstitial space might be taken up non-selectively by cancer cells that do not express the target epitope; this results in cytotoxicity by the "bystander effect" (e.g., immunoliposomes and ADEPT). (d) Immunotoxins must be internalized to show cytotoxicity, so no opportunity for a bystander effects exists. Reproduced with permission from ref. [33]

Interleukins, especially IL-2, have been exhaustively studied for tumor immunotherapy. High dose IL-2 was the pioneer immunotherapy approved for treatment of melanomas and had complete response of ~6 % and partial response of ~10 % [216]. However, it is associated with severe side effects such as vascular leak syndrome, hypersensitivity reactions, etc. In contrast, the immunocytokines therapy demonstrated remarkably higher tumor accumulation of cytokines without notable compromise in safety profile [217]. In another set of experiments, 20-fold higher potency was noted for antibody targeted IL-12 in contrast to that of naked IL-12 [218]. On these grounds, a variety of immunocytokines based products such as Proleukin™, Aldesleukin™ comprising IL-2; Beromun™ comprising TNF-α; Roferon-A™ and Intron-A™ comprising interferon-α2; and Leukine™ and Leucomax™ comprising granulocyte-macrophage colony-stimulating factor (GM-CSF) have been approved clinically [219]. In parallel, the exploration of




Fig. 2.12 Working mechanism of immunocytokines exemplified for tumor targeted IL-2. A monoclonal antibody specific for a tumor-associated antigen allows the enrichment of cytokines in the tumor microenvironment. In the case of interleukin-2 (IL-2) it enhances antibody-dependent cellular cytotoxicity mediated by Fc-receptor positive effector cells such as natural killer cells. In addition, tumor-targeted IL-2 stimulates T cells to expand and attack the tumor. High concentrations of plasmin at the tumor site enable the cleavage of IL-2 from the fusion protein through the plasmin cutting site within the linker (depicted in the figure by scissors). Reproduced from ref. [211]

cytokines as vaccine adjuvants is also in move. Upon combination with dendritic cells interesting memory immune responses were noted in the sense that site specific memory response mediated by effector memory T cells was executed whereas the central memory T cells were not formed [220]. The hypothesis was based on the fact that in rechallenge test the no tumor relapse was observed in organ in concern whereas tumor was induced in other organs. Recently, complete eradication in the B-cell lymphoma xenograft was observed upon treatment with combination of rituximab and L19-IL2 [221]. Similar results were also noted when L19-IL2 combined with (Cytotoxic T-Lymphocyte antigen 4) CTLA-4 blockade or L19-TNF [222]. Of note, not all cytokines exhibit antitumor effects, lymphotoxins represent a class of cytokines leading to physiology of tumorigenesis mediated by inflammatory pathways [223]. The said discrepancy could possibly be attributed to the typical structural motif of lymphotoxins which is trimeric in contrast to that of heterodimeric structure of potent antitumor cytokines such as IL-12 [185]. Hence, while employing immunocytokines based cancer therapy, the alterations in allied pathways and its clinical implications should be considered. Table 2.8 depicts various immunocytokines employed for cancer immunotherapy.

Table 2.8 List of immunocytokines employed for cancer immunotherapy

Cytokine	Monoclonal antibody	Outcomes	Ref.
IL-2	2aG4, PS targeting antibody	80 % of mice inoculated with 2aG4-IL2/4 T1 vaccine survived free of tumor and significantly increased 4 T1 specific cytotoxicity and ability to secrete interferon gamma (IFN γ)	[224]
IL-2	14G2A antibody	Uterine leiomyosarcoma diffusely expressed GD2 and binds the therapeutic immunocytokine 14.18-IL2 and shown to be a potential target for effective management of aggressive tumors	[225]
IL-2	F8 antibody	F8-IL2 effectively inhibited the growth of EDA-Fn-expressing melanomas in combination with paclitaxel as a result of recruitment of F8-IL2-induced natural killer (NK) cells to the tumor via paclitaxel mediated enhanced tumor perfusion and permeability.	[226]
IL-2	F16 antibody	Selective tumor staining of F16 and preferential tumor accumulation of radiolabeled F16-IL2	[227]
IL-2	L19 and anti-CTLA-4 antibody	L19-IL2 exhibited complete tumor eradications when used in combination with CTLA-4 blockade	[222]
IL-2	F8 antibody	28 % cure rate and substantial tumor growth retardation were observed for the combination of sunitinib with F8-IL2 immunocytokine	[228]
IL-2	hu14.18 antibody	Patients treated with hu14.18-IL2 immunocytokine developed anti-idiotypic antibodies and anti-Fc-IL2 antibodies	[229]
IL2	huKS antibody	Paclitaxel and cyclophosphamide followed by huKS-IL2 resulted in enhanced antitumor responses against CT26/KSA colon, 4 T1/KSA mammary and LLCKSA Lewis lung carcinomas due to increased uptake of the huKS-IL2 immunocytokine into the tumor microenvironment by the virtue of reduced diffusion barrier by drug therapy	[230]
IL2	huKS antibody	Significantly increased (complete tumor resolution in 50 % of mice) the antitumor effect of RFA (Radiofrequency ablation) by combining it with huKS-IL2. Immunocytokine also showed antitumor effects against distant untreated tumor and greater proportion of cytokine-producing CD4 T cells and CD8 T cells	[231]
IL-7	F8 antibody	Improved tumor targeting performance with tumor: blood ratio = 16:1	[232]
IL-12	NHS76 antibody	Significant increase in the toxicity profile of NHS-IL12 was achieved as a result of attenuated IFN gamma production, selective targeting and longer half-life	[233]

(continued)

Table 2.8 (continued)

Cytokine	Monoclonal antibody	Outcomes	Ref.
IL-12	SS1 Fv	IL12-SS1 (Fv) immunocytokine significantly inhibited human tumor expressing mesothelin proteins, i.e., malignant mesothelioma (NCI-H226) and ovarian (OVCAR-3) cells as well as recombinant mesothelin on A431/H9 cells	[234]
IL-12	Recombinant human antibody fragment L19	Antitumor activity of EMD 521873 (Selectikine immunocytokine) was reported in heterogeneous patient population as prolonged disease stabilisation and a transient drop in tumor markers and also it was found that at all dose-levels there were transient increase in total lymphocyte, eosinophil, and monocyte counts	[235]
IL-15, GMCSF	L19 antibody	L19-IL-15 and L19-GM-CSF displayed a potent antitumor activity via CD8+ T cells	[236]
IFN- α	hRS7, hMN 15, hL243, and c225 antibodies	Up to 1,000-fold improved anti-proliferative potency of IFN- λ 1, when tethered with antibodies hRS7, hMN 15, hL243, and c225, was demonstrated against targeted cancer cell lines along with increased antiviral activity against encephalomyocarditis virus and hepatitis C virus IFN- λ 1 via (15)- λ 1 or (c225)- λ 1 respectively	[237]
IFN- γ	Anti-CD70 antibody	Anti-CD70 IFN- γ immunocytokines displayed high levels of species specific IFN- γ activity and selective binding to CD70 on human RCC cells and higher tumoricidal activity by the virtue of RIP1-dependent necrosis in RCC cells in the presence of bortezomib	[238]
TNF	scFv23	scFv23/TNF was found to be highly cytotoxic to TNF-resistant HER-2/neu-expressing pancreatic cancer cell lines and demonstrated a synergistic cytotoxic effect with 5-fluorouracil (5-FU) by the virtue of downregulation of HER-2/neu, p-Akt, Bcl-2 and upregulation of TNF-R1, caspase-8, and caspase-3	[239]

2.5.3.4 Antibody Directed Enzyme Prodrug Therapy (ADEPT)

ADEPT represents an improved version of cancer immunotherapy among the above discussed strategies for efficient management of advanced malignancies and solid tumors. Classical immunotherapies face challenges such as limited penetrating capabilities, need for internalization, antigen heterogeneity, nonuniform drug release and subsequent altered potency levels. Principally, ADEPT operates via usage of antibodies specific for tumor agents that are covalently linked to enzyme in the concern. In the first step, such antibody–enzyme conjugate is administered to the patients and allowed to preferentially localize in the vicinities of tumor. Once the unbound conjugates are cleared of the body by a variety of means, a prodrug




Fig. 2.13 Basic principle of ADEPT. *Stage 1*, administered AEC is allowed to localize at site of action. *Stage 2* the excess circulating prodrug is cleared of the blood. *Stage 3* nontoxic prodrug is administered that specifically generates active at site of action

sensitive to pre-targeted enzyme is administered which will generate very high local concentrations of active drug in the extracellular regions of tumor. The active drug can then be passively internalized within cells and impart cytotoxicity (Fig. 2.13) [240]. One of the promising advantages is bystander effects which also impart cytotoxicity to antigen negative cells (Fig. 2.11) [241].

The principal components of ADEPT include target, antibody, enzyme, abenzymes/catalytic antibodies, and prodrugs [242]. Firstly, target should usually be native to the tumor and should have minimal expression over normal tissues. However, it is practically difficult to find such targets and hence care should be taken that normal expression of target is at minimal at least on the vital organs so to avoid any irreparable damages to the critical body organs. However, heterogeneity among in antigen expression in epithelial tumors is quite common. Furthermore, the internalization of the antibody–enzyme conjugate should be avoided so as to avoid failure of therapy. The additional advantage of the surface linked enzyme is rapid conversion of many prodrug molecules and higher tumoral concentrations. While selecting target antigen, care should also be taken that it should not be secretory in nature; however, there have been some exceptions such as ADEPT in the case of human chorionic gonadotrophin (hCG) producing tumors was successful in spite of higher concentrations of hCG in central compartment [243].

Secondly, antibody plays an important role in preferentially localizing the enzymes and hence the therapeutics at the target location so as to achieve the maximum benefits, *per se*. This retention of enzymes at the target site may extend up to several days. In this regard, considering the binding affinity of the employed antibody, interplay of antibody–enzyme conjugate in the vicinity of tumor and in central compartment could be modulated with ideal situation being nil antibody–enzyme conjugate in central compartment for achieving maximum therapeutic efficacy. Such highly stable antibody complex could be achieved by employing class I or II IgG monoclonal antibodies. Furthermore, this balance could be modulated in a better way by usage of antibody fragments such as F(ab)₂ which are associated with principal advantages of rapid clearance from the central compartment imparting better targeting potential to the tumors; however, the binding affinity, size of fragment, renal clearance and hence total available enzymatic concentrations at the site of action, etc. should be taken into account while comparing it with whole antibodies [244].

Thirdly, enzyme has principal role for success of ADEPT. However, there lies certain restriction on type of enzymes which could be used such as human enzymes exhibit wide normal tissue distribution while nonhuman enzymes face problems of immunogenicity and possible human isoforms in physiological conditions. Among the available options, bacterial enzymes are explored considering their potential efficiency to a greater extent; however, their immunogenicity is debatable. In purview of decreasing the immunogenicity, efforts are being to identify the responsible amino acid sequences and their suitable replacement in modified enzymes [245, 246]. In this regard, yet another interesting concept of preparing mutant human enzymes is prevailing which will enable the prodrug processing only by mutated enzymes, whereas original human forms of these enzymes remain inactive, e.g., T268G mutant of human carboxypeptidase A1 for prodrugs of methotrexate [247]. Table 2.9 lists various enzymes employed for ADEPT.

Fourthly, the concept of catalytic antibodies is also emerging as promising component of ADEPT with the principal advantage of overcoming immunogenicity related problems [267]. Conceptually these are improved version of therapeutic antibodies which are equipped with additional enzymatic catalytic power (Fig. 2.14). The most classical methods to prepare such catalytic antibodies are transition state analogue approach, hapten substrate approach and reactive immunization approach. Their immense clinical relevance arises from the promising advantages such as improved circulation half-life in central compartment, increased specificity and affinity for the target and prodrugs, and feasibility to exploit antibody/genetic engineering along with the classical advantage of low immunogenicity. Some examples of catalytic antibodies include 38C2 for aldolase activity; 84G3, 85H6, 90G8, and VHHC10 for aliinase activity; 3D8-VL for mRNA of HER2 hydrolysis; A17 for degradation of organophosphate compounds, ETNF-6-H for hydrolysis of TNF- α , etc. Recently, cell targeting and prodrug activation capabilities of the next generation therapeutic antibody, catalytic Ab 38C2, have been established in the case of selective tumor immunotherapy with doxorubicin prodrugs [268].

Table 2.9 List of enzymes employed for ADEPT based cancer immunotherapy

Enzyme	Characteristics	Ref.
β -glucosidase	β -glucosidase conjugated with tumor associated monoclonal antibody HMFG1 enhances the cytotoxic effect of amygdalin by 36-fold while increased rate of survival of U87MG (HMFG1-negative) cells	[248]
β -glucuronidase	After fusion with a humanized single-chain antibody (scFv) of mAb CC49 to S2 (a human β -glucuronidase (h β G) variant) displays enhanced human enzyme catalytic activity and more effective in killing antigen-positive cancer cells	[249]
β -Lactamase	Fusion protein TAB2.5 (conjugation of CC49 and β -lactamase) showed prolonged retention ($T_{1/2}$ = 36.9 h) with tumor to plasma ratios of up to 1,000	[250]
β -Lactamases	When fused with ACDCRGDCFCG peptide (RGD4C), it found to be active for specificity in MCF-7 cell lines	[251]
Carboxypeptidase-A	Anti-seminoprotein (SM) single-chain antibody/human carboxy peptidase A fusion protein (scFv/hCPA) mediated hydrolysis of methotrexate prodrug increased cytotoxicity up to 1,000-fold with no systemic toxicity of the prodrug	[252]
Carboxypeptidase A	HuA33 antibody-carboxy peptidase A (acts on methotrexate phenylalanine prodrug) demonstrates higher specificity of tumor uptake with eightfold reduced cytotoxicity (LD50 of MTX) to non-tumor sites	[253]
Carboxypeptidase G2 (CPG2)	Conjugation of CPG2 with SB43 anti-carcinoembryonic antigen antibody fragment A5B7-F(ab') ₂ shown to reduce the percentage of injected dose per gram in blood and a tumor-to-blood ratio of 45: 1 at 24 h, which increased to 100: 1 at 72 h	[254]
Carboxypeptidase G2 (CPG2)	F(ab') [SUB2] anti-CEA antibody A5B7 and the bacterial enzyme CPG2 conjugates converts ZD2767P (4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L-glutamic acid) to ZD2767 (bifunctional alkylating agent) at the tumor site which resulted in 229-fold increase in activity.	[255]
Carboxypeptidase G2 (CPG2)	Anti-carcinoembryonic A5B7 conjugated to the bacterial enzyme carboxypeptidase G2 acts on the prodrug 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid resulted in significantly enhanced tumor growth with no concomitant increase in systemic toxicity	[256]
Carboxypeptidase G2 (CPG2)	MFECF, a recombinant fusion protein of CP with MFE-23, a single chain Fv (scFv) antibody, modified to hexahistidine tag (His-tag) MFECF found to have significantly reduced human antibody response	[257]
Cytosine deaminase (CD)	Fused LinkCD, hyaluronan binding domain of TSG-6 (Link) and yeast cytosine deaminase (CD) with an N-terminal His(\times 6) tag shown to have increased duration of the enzyme activity and significant tumor size reduction in animals that received LinkCD/5-FC treatment	[258]

(continued)

Table 2.9 (continued)

Enzyme	Characteristics	Ref.
Cytosine deaminase (CD)	Fusion of anti-gpA33 single chain fragment, A33scFv, with cytosine deaminase from yeast (CDy), which converts 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), results demonstrate bifunctional activity of A33scFv::CDy fusion protein which is equally cytotoxic to equimolar amounts of 5-FU	[259]
Human β -glucuronidase (β G)	chTNT-3 and β -glucuronidase enzyme fusion protein (acts on doxorubicin glucuronide prodrug), specifically localize to tumor sites with rapid clearance from blood and normal tissues	[260]
Human β -glucuronidase (β G)	It was found that ortho-substituted phenyl carbamates (i.e., N-[4-O-(Methyl- β D-glucopyranosyluronate)-3-nitrobenzyloxycarbonyl] doxorubicin) are better substrates for fusion protein human β -glucuronidase-humanized CEA than the corresponding para-substituted analogues	[261]
Human β -glucuronidase (β G)	Anti-CD20 mouse monoclonal antibody (MoAb) 1H4 and human β -glucuronidase activates nontoxic prodrug N-[4-doxorubicin-N-carbonyl(-oxymethyl) phenyl] O- β -glucuronylcarbamate to doxorubicin at the tumor site	[262]
Mutant human purine nucleoside phosphorylase	Double mutant with amino acid substitutions E201Q:N243D (hDM) is the most efficient in cleaving (deoxy) adenosine-based prodrugs, i.e., 2-fluoro-2'-deoxyadenosine to a cytotoxic drug	[263]
Mutant human carboxypeptidase A1, changed at position 268 from the wild type threonine to a glycine (hCPA1-T268G)	hCPA1-T268G was conjugated to ING-1 (antibody that binds to the tumor antigen Ep-Cam) or to Campath-1H (an antibody that binds to the T and B cell antigen CDw52) which acts on MTX- α -3-cyclobutylphenylalanine and MTX- α -3-cyclopentyltyrosine prodrugs releasing free methotrexate. It is found that ING-1:hCPA1-T268G conjugate produced excellent activation of the MTX prodrugs to kill HT-29 cells as efficiently as MTX itself	[247]
Mutant prolylendopeptidase (Glu289 \rightarrow Gly)	Mutant human prolyl endopeptidase was chemically conjugated with L19 human antibody, a marker of angiogenesis which acts on the prodrug N-protected glycine-proline dipeptide doxorubicin or melphalan, i.e., Benzyloxycarbonyl) glycylylprolyl melphalan producing free melphalan	[264]
Nitroreductase enzyme	It bioactivates CB 1954 (alkylating agent) much more rapidly than Walker DT diaphorase as a result it overcomes the intrinsic resistance of human cell lines towards CB 1954	[265]
Penicillin-V amidase (PVA)	Folate-PVA- ¹²⁵ I (PVA covalently labeled with three molecules of folic acid) which converts doxorubicin-N-p-hydroxy phenoxyacetamide prodrug (DPO) into its potent parent drug, doxorubicin, bind specifically to KB cells (FR-positive tumor cells) but not to A549 cells (FR-negative tumor cells) with higher clearance from the blood	[266]

Fifthly, prodrugs remains the fundamental and rate limiting component of ADEPT. The ratio of activity of therapeutically active form to the inactive form majorly determines the potency of the ADEPT in concern and this ratio usually ranges from 100 to 1,000 s. Classically it is anticipated that the dose response of the




Fig. 2.14 Conceptual understanding of catalytic antibody

active drugs should be concentration dependent and should ideally have very low decay half-life so as to avoid any detrimental effects to the normal tissues from the drug that leaked into central compartment.

Recent trend in the field of ADEPT include design and developments in the field of two and three phase systems. Apart from activation of prodrug at tumor site, efforts are being made to rapidly clear the antibody–enzyme conjugates from the blood compartment in the view to avoid any possible toxicity to the normal tissues. The hypothesis has been classically tested in LS174T xenografted mice administered with monoclonal anti-carcinoembryonic antigen antibody fragment A5B7-F(ab')₂ conjugated to a bacterial enzyme, carboxypeptidase G2 (CPG2) [254]. Among the tested approaches, the first comprised inactivator of CPG2, SB43, which was galactosylated and administered to clear out plasma antibody–enzyme conjugates mediated by carbohydrate receptor in liver. Interestingly, upon optimizing dose schedule, minimal compromise in therapeutic efficacy could be achieved. The second approach in contrast includes direct galactosylation of the antibody–enzyme conjugate in a manner such that binding affinity with the tumor antigen is altered. The said conjugate acts on receptor saturation mechanism and either rapidly bound to tumor tissues or cleared from the plasma cumulatively leading to almost 100-fold tumor to blood ratio of antibody–enzyme conjugates.

Furthermore, on similar line of ADEPT, Gene directed enzyme prodrug therapy (GDEPT) has also been widely explored for its potential in improving the tumor delivery of anticancer therapeutics. It is also referred to as suicide gene therapy (SGT), virus directed enzyme prodrug therapy (VDEPT), and gene prodrug activation therapy (GPAT). The principal difference herein is the activation of drug at intracellular level in contrast to ADEPT which releases the drug in extracellular matrices. The principal examples include activation of cyclophosphamide and ifosfamide using cytochrome p450, 5-fluorocytidine and 5-fluorouridine using cytosine deaminase, etc. Primarily, the tumor specific regulatory element and gene encoding enzyme is loaded in a suitable colloidal carrier system which upon reaching at

intracellular levels results in transgene expression and leads to execution of prodrug activation system, thereby imparting cell cytotoxicity [269].

2.5.3.5 Immunoliposomes

Liposomes represent an important class of nanocarriers with established applicability in a variety of disease conditions and difficult-to-deliver therapeutics. Though concomitant with widespread applicability, there also lie some negative points such as rapid clearance from the plasma process of opsonization of proteins on the surface of plain phospholipid vesicles. However, with the advent of PEGylation, the problem has been addressed to some extent and some quality products have made their way to clinical practice such as Doxil®. This stealth property of hydrophilic coatings enable liposomal drug delivery system to evade the reticuloendothelial systems and lead to preferential localization in the vicinity of extracellular tumor matrices by so-called enhanced permeation and retention effect [270]. However, in the purview of further increasing the therapeutic potential of these sophisticated colloidal drug delivery systems to tumor tissues, antibody targeting could be sought for. Structurally, these comprise stealth liposomes end functionalized with antibody, usually referred to as immunoliposomes [271]. Both whole antibody and antibody fractions specific to tumor antigens have been exhaustively used for exploring the potential of immunoliposomes for cancer therapy.

In the purview of formulation development, numerous methods have been proposed till date for linking antibodies to liposomal surface; however, post insertion technique remains the most viable and widely accepted [272]. In some instances, even the micelles of PEG linked antibodies have been incubated with marketed liposomal products to form immunoliposomes [273]. The classical chemical strategies include linking hydrazine group of PEG chains with oxidized carbohydrate group of oligosaccharide portion of antibody, maleimide group linked with thiolated antibodies, pyridyldithio propionate method, and biotin–avidin method [274]. Employing these chemistries numerous antigen targeted ligands have been linked to liposomes; however, the fruitful alteration in the various physicochemical properties of immunoliposomes and its optimization is still underway. Primarily, internalizing antibodies are employed for achieving significant appreciation in the therapeutic efficacy such as CD19 epitopes for B-cell lymphomas [275]. Figure 2.15 depicts various internalization mechanisms with liposomal drug delivery systems. Recent trends include combining immunoliposomes with endosome disruptive peptides for improved cytosolic delivery of therapeutics such as fusogenic peptide diINF-7 linked liposomes targeted to ovarian carcinoma [276].

The principal advantage associated with immunoliposomes is the very high drug payload as compared to any other available immunotherapies. Secondly, liposomal surface pose maximum capability to link the antibodies than classical immunotherapeutic approaches. This feature could be fruitfully exploited in employing monovalent antibody fragments, thereby eliminating the need of formation of scFv fragments by excessive antibody engineering to improve upon their valences and




Fig. 2.15 Internalization of liposomal drug delivery systems. (A) Plain liposomes are entitled for either specific adsorption (a), nonspecific adsorption at cell surface (b) fusion with cell membrane (c), destabilized of liposomes upon adsorption at cell surface by internal components (d), direct or transfer-protein-mediated exchange of lipid component (e) and endocytosis (f). The endocytosed liposomes either fuses with lysosomes (g) or leads to endosomal escape and drug delivery to cytoplasm (h). (B) Surface functionalization of the liposomes with appropriate ligands can be performed (a) to interact with target receptors (b), followed by endocytosis (c), and drug release (d)

hence binding affinity [271]. The concept of immunoliposomes has emerged since old times and in numerous instances, potential has been established. Table 2.10 lists various approaches for immunoliposomes based drug delivery for efficient management of cancer [277].

2.5.3.6 Immunopolymers

Blending polymer engineering with antibody engineering is probably the most recent era of immunotherapy. Polymer based drug delivery is widely accepted as one stop solution for almost all kinds of therapeutics ranging from small molecules, nucleic acid, proteins, peptides, hormones, etc. The barriers of physicochemical properties of said therapeutics can be efficiently circumvented by designing apt polymeric drug delivery system. With the advent of antibody directed polymers, plethora of chemically and functionally diverse synthetic yet biomimetic systems have been explored in last couple of decades [294]. The principal advantages associated with antibody conjugation with polymers includes significant appreciation in solubility, immunocompatibility, favorable pharmacokinetics, improved stability,

Table 2.10 List of immunoliposomes based drug delivery system for cancer immunotherapy

Antibody	Drug(s)	Indication/target	Outcomes	Ref.
Anti-EGFR (epidermal growth factor receptor) Fab	Adriamycin and ribonucleotide Reductase M2 siRNA	EGFR positive hepatocellular carcinoma(HCC)	Targeted LPD (liposome–polycation–DNA complex) conjugated with anti-EGFR (epidermal growth factor receptor) Fab' co-delivering adriamycin (ADR) and ribonucleotide reductase M2 (RRM2) siRNA (ADR-RRM2-TLPD) was prepared with enhanced therapeutic effects	[278]
Anti-EGFR-Fab	siRNA	MDA-MB-231 breast cancer cells	TLPD-FCC (Targeted liposome–polycation–DNA complex conjugated with anti-EGFR Fab' by conventional conjugation) showed significantly enhanced binding affinity and luciferase gene silencing activity by ~20 % in EGFR	[279]
Anti-EGFR-Fab	siRNA	SMMC-7721 hepatocellular carcinoma cells	Two PEG derivative linkers (DSPE-PEG-COOH and DSPE-PEG-MAL) were used to develop immunoliposomes. Immunoliposomes derived from DSPE-PEG-MAL (TLPD-FPM) shown to have significantly greater cellular uptake and up to threefold higher luciferase gene silencing efficiency than that of TLPD-FPC	[280]

(continued)

Table 2.10 (continued)

Antibody	Drug(s)	Indication/target	Outcomes	Ref.
Anti-EGFR and anti-HER2	Topotecan (TPT)	HER2 overexpressing human breast cancer (BT474)	Stabilization of topotecan in nanoliposomes significantly improves the targetability and pharmacokinetic profile of topotecan	[281]
Anti-HB-EGF	Doxorubicin	HB-EGF positive breast cancer	Results showed selective binding and uptake of the immunoliposomes in HB-EGF-expressing cells	[282]
Antinucleosome monoclonal antibody 2C5	Doxorubicin	Nucleosome	Significant reduction in tumor growth and enhanced therapeutic efficacy of the drug in both drug resistant and drug sensitive mice was obtained	[283]
Anti-VEGFR2	Doxorubicin	HT-29 human colon cancer/MMTV-PyMT mouse model of breast cancer	Histopathological and molecular analysis revealed strong antiangiogenic effect of anti-VEGFR2-ILs-dox (Anti-VEGFR2-targeted immunoliposomes (ILs) loaded with doxorubicin)	[284]
Anti-RON antibody Zt/c9	Doxorubicin	CD24+, CD44+, ESA + (triple positive) pancreatic L3.6pl cancer cells	Anti-RON antibody Zt/c9-directing doxorubicin-immunoliposomes (Zt/c9-Dox-IL) was developed which specifically interacted with CSCs ^{+24/44/ESA}	[285]
Anti-RON antibody Zt/g4	Doxorubicin	Hypoxic colon HCT116 and SW620 cells	Zt/g4-Dox-IL was found to be effective in killing hypoxic HCT116 and SW620 cells with reduced IC ₅₀ values compared to Dox and pegylated-liposomal Dox	[286]

(continued)

Table 2.10 (continued)

Antibody	Drug(s)	Indication/target	Outcomes	Ref.
Cetuximab (α -hEGFR)	–	Glioblastoma multiforme	In vitro studies revealed significantly higher binding of α -hEGFR-ILs (PEGylated immunoliposomes conjugated with anti-human epidermal growth factor receptor (EGFR) antibodies) when compared with liposomes conjugated with isotypic nonimmune Ig resulting in enhanced uptake and accumulation of liposomes	[287]
Cetuximab	Doxorubicin	Human ovarian adenocarcinoma (SKOV3, SKOV3.i.p.1) cells	Shown efficient and specific receptor-mediated binding to ovarian carcinoma cells	[288]
IGFI-R antagonistic antibody (1H7)	Doxorubicin	Neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs)	Anti-IGFI-R immunoliposomes displayed specific tumor cell and internalization in human neuroendocrine tumor cells in vitro and superior antitumor efficacy in vivo	[289]
mAb 2C5	Doxorubicin	B16-F10, HeLa, and MCF-7 cell lines	Multifunctional immunoliposomal nanocarrier with pH-sensitive PEG-PE component, TATp and the cancer cell specific mAb 2C5 showed enhanced cytotoxicity and internalization by cancer cells	[290]
Trastuzumab	Bleomycin	HER2 positive human breast cancer	Immunoliposomes showed enhanced cytotoxicity towards HER2 positive MCF-7/Her18 cells and also affect trastuzumab-resistant MDA-453 cell	[291]

(continued)

Table 2.10 (continued)

Antibody	Drug(s)	Indication/target	Outcomes	Ref.
Trastuzumab	Curcumin and resveratrol	HER2 positive human breast cancer	Significant increase in the antiproliferative effects of curcumin and resveratrol in HER2 positive human breast cancer cells as a result of enhanced uptake of curcumin and resveratrol at intracellular level	[292]
Trastuzumab	Docetaxel	Her2/neu positive gastric tumor	Docetaxel-loaded immuno (trastuzumab) liposomes (IDL) showed a significantly higher distribution of docetaxel in the N87 xenograft tumor tissues and superior antitumor efficacy	[293]

relatively higher cellular uptake, reduced aggregation, relatively higher antibody payload, feasibility to modulate intracellular trafficking, etc. Recent advances in the field of recombinant technology has enable the use of a variety of products such as isolated antibodies and their fragments including humanized, tumor biomarkers, structural components of microbes, natural and synthetic sources of immunostimulators.

Immunopolymers primarily comprise antibody (either whole antibody or antibody fragments) linked to polymers (may be functionalized for specific applications). Recent advances in the field of antibody engineering enable the de novo design and development of antibody fragments for a variety of end applications [295]. These antibody fragments when linked to polymeric counterparts avail additional advantage of relatively higher binding density owing to smaller size [296]. PEGylation of antibody fragments has been explored to a greater extent in improving the circulation half-life, per se. A variety of approaches employed for linking these antibody fragments to polymer backbone include thiol modifications, linking via sugar portions, fusion proteins, etc. Generally, either N- or C- terminal end of the antibody fragments is opted for modifications; however, in some cases such as in scFvs inter-domain peptide linker may be sought for without any compromise in binding affinity [297]. Recently, novel functionalities in the scFvs could be added employing a variety of protein and chemical engineering approaches such as tagging with hexahistidine or streptavidin for site specific conjugation or delivery [298]. Similarly, C-terminal cysteine modification has also been greatly explored and could lead to ~100-fold appreciation in circulation half-life [299]. Furthermore, PEGylation of scFvs also render the resulting immunopolymers resistant to proteolytic enzymes [300]. Owing to these functionalities, PEGylated antibody fragments have been widely explored from tumor targeting perspectives. In a representative

study, PEGylated di(Fab') exhibited significantly higher antitumor efficacy as compared to PEGylated IgG and the latter being comparable to that of plain IgG in xenograft tumor bearing thymic mice [301]. Similar results were also noted in case of PEGylated anti-CEA F(ab')₂ exhibiting significant increase in circulation half-life and tumor accumulation [302]. In separate set of experiments effect of molecular weight of PEG was also studied and it was found that higher molecular weights in the order of 25 kD tend to localize equally within normal tissues also in contrast to that of low molecular weights (~5 kD) [303]. In an interesting study, ¹¹¹In-cysteinyl-DOTA-PEG3400-diabody conjugate and ¹²⁵I-PEG3400-diabody were explored for its potential in imaging liver metastasis in a nude mouse xenograft model (Fig. 2.16) [304].

Apart from PEGylated antibodies, stimuli responsive polymers represent yet another area where antibodies are being explored to a greater extent. Classically, these stimuli responsive polymers are sensitive to pH, temperature, presence of




Fig. 2.16 Radioimmunoimaging of (a) ¹¹¹In-cys-DOTA-PEG3400-diabody and (b) ¹²⁵I-PEG3400-diabody in nude mice bearing LS174T xenografts. Reproduced from ref. [304]

small molecules such as amino acids, external energies such as electrical and magnetic, etc. [294]. In this domain, *N*-(2 hydroxy propyl) methacrylamide (HPMA) has been exhaustively explored. Significant increase in the cell cytotoxicity of Fab' was noted against ovarian carcinoma when co-polymerized with HPMA [305]. On similar line of action, galactosylated HPMA conjugate comprising doxorubicin with Gly-Phe-Leu-Gly spacer revealed great clinical potential with notable responses in hepatoma patients [306]. Mechanistic studies with anti-Thy1.2 targeted or CD71 targeted HPMA polymers further revealed preferential nuclear localization tendencies intracellularly [307]. Recent advances in the field of polymer drug conjugates include its combination with ADEPT and the resulting therapy is referred to as polymer directed enzyme prodrug therapy (PDEPT) where combination of polymeric prodrug and polymer enzyme conjugate is employed to impart cytotoxicity at the site of action. PK1-HPMA copolymer-Gly-Phe-Leu-Gly-doxorubicin conjugate in combination with HPMA copolymer-cathepsin B led to 4.2-fold higher tumor accumulation in B16F10 tumor bearing mice as compared to plain free enzyme [308]. Table 2.11 lists immunopolymers employed for improving the deliverability of antibodies.

2.5.4 Targeting Multidrug Resistant Tumors

The principal problem associated with the advanced anticancer therapeutics, i.e., molecular targeted therapies and immunotherapy are increased chances of resistance and inter-, intra-tumor variability, often leading to poor therapeutic responses. Broadly, two factors have been considered responsible for multidrug resistance, viz., cellular and physiological factors [319]. The former includes a variety of genetic alterations at cellular levels such as efflux transporters, whereas the latter is more focused on the physicochemical changes at tissue levels such as pH, extracellular interactions and peculiar tumor microenvironment (Fig. 2.17). Based on these factors, efflux of the bioactives is regarded as most common mechanism of drug resistance in cancer therapeutics [320]. A variety of approaches could be employed to counterfeit drug efflux systems and these include pharmacologically active P-gp inhibitors, functional excipients such as natural polymers, surfactants, lipids, cyclodextrins, polyethylene glycol and derivatives, thiolated polymers, etc. [16].

Furthermore, in purview of increasing therapeutic responses in cancer chemotherapy and sensitize the multidrug-resistant tumors, nanotechnology seems to be most efficient approach. Recent advances in the field of nanocarrier based approaches have paved the way to efficiently deliver therapeutics to multidrug resistant cancer therapy and includes polymeric nanoparticles, lipid nanocarriers, dendrimers, carbon nanotubes and inorganic nanocarriers, to name a few. The principal focus of employing nanocarriers relies on improving the interactions with target cells, enhanced internalization mechanisms, tumor specific biodistribution pattern, availing benefits of "click chemistry," reducing the nonspecific binding, tailoring the ligand properties such as choice of ligand and its density, charge, orientation, etc. [322].

Table 2.11 List of immunopolymers employed for improving the deliverability of antibodies

Antibody	Polymer	Outcomes	Ref.
Anti-CD20 monoclonal antibody	HPMA	Cytostatic activity of the anti-CD20 monoclonal Ab-targeted conjugates tested on several CD20-positive or negative human and mouse cancer cell lines confirmed considerable targeting capacity of the monoclonal Ab after its binding to the polymer carrier	[309]
Anti-EGF receptor antibody	DSPE-PEG lipid polymer complex	In vivo accumulation of PLNP-Mal-EGFR was found to be higher than that of nontargeted nanoparticles in SMMC-7721 HCC cells overexpressing EGFR with enhanced antitumor activity against HCC compared with nontargeted nanoparticles and free adriamycin	[310]
Anti-HER2-affibody-anti-DTPA-Fab complexes (BAAC), anti-DTPA-Fab	Polyglutamic acid	There was no total body weight (TBW) loss at three times the doxorubicin equivalent maximum tolerated dose (MTD) with D-Dox-PGA. Therapeutic efficacy was equivalent in mice pre-targeted with BAAC/ targeted with D-Dox-PGA to mice treated only with doxorubicin	[311]
Anti-PSMA antibody	HPMA	Rate of endocytosis of P-anti-PSMA was much faster than that of control HPMA copolymer conjugates containing nonspecific IgG via clathrin-mediated endocytosis, macropinocytosis, and clathrin-, caveolae-independent endocytosis	[312]
Catalytic antibody 38C2	HPMA	Catalytic antibody-HPMA copolymer conjugate was evaluated in vitro for its ability to activate an etoposide prodrug and it was found that the inhibition using the prodrug and the conjugate was almost identical to inhibition by the free antibody and the prodrug	[313]
HD39 monoclonal antibody	Poly(propylacrylic acid) (PPAA)	Subcellular fractionation studies of HD39/SA-PPAA conjugates showed 89 % of HD39/SA was associated with endosomes (Rab5+) and lysosomes (Lamp2+), while 45 % of HD39/SA-PPAA was translocated to the cytosol (lactate dehydrogenase+) which demonstrate the endosomal releasing properties of PPAA with antibody-polymer conjugates	[314]
Monoclonal anti-RAGE and polyclonal human Ig (huIgG)	Poly(<i>N</i> -(2-hydroxypropyl)-methacrylamide) (poly-HPMA)	Antibody polymer conjugate, two different model antibodies, monoclonal anti-RAGE and polyclonal human Ig (huIgG) antibodies, were attached to maleimide functionalized poly(<i>N</i> -(2-hydroxypropyl)-methacrylamide) (poly-HPMA) through reversible addition-fragmentation chain transfer (RAFT) polymerization of pentafluorophenyl methacrylate via the intermediate step of an activated ester polymer was developed with preserved affinity	[315]

(continued)

Table 2.11 (continued)

Antibody	Polymer	Outcomes	Ref.
HPMA	Polyclonal and monoclonal anti-Thy 1.2 or anti-Ia ^k antibody	Daunomycin toxicity of daunomycin-antibody-copolymer conjugate against hematopoietic precursors in bone marrow colony forming unit spleen was found to be decreased up to 80-fold and with no significant irritation of Kupffer cells in liver	[316]
OV-TL16 antibody	Pegylated polyethylenimine (PEG-PEI)	Sixfold higher degree of binding of PEG-PEI-Fab/DNA complexes to OA3 positive human ovarian carcinoma cell lines compared to unmodified PEG-PEI/DNA complexes and up to 80-fold increase in luciferase reporter gene expression compared to PEG-PEI	[317]
Polyclonal rabbit anti-mouse thymocyte globulin (ATG)	Poly(ethylene glycol) (PEG)	Antibody polymer drug conjugates exhibited significant antitumor efficiency against murine T-cell EL 4 lymphoma in vivo	[318]




Fig. 2.17 Factors influencing tumor heterogeneity and drug resistance. Genetic, nongenetic, and microenvironmental factors give rise to tumor heterogeneity, which significantly influences the drug sensitivity of cancer cells through an array of cellular mechanisms, such as transporter overexpression. Reproduced from ref. [321]

2.6 Conclusion and Future Prospects

Recent advances in the field of tumor targeting focus on the design and development of highly sophisticated molecules with high tumor specificity. Molecular targeted therapies are rapidly changing its paradigm towards tumor specific antigen and have reached quite near to the original concept of *magic bullet*. Furthermore, in combination with antiangiogenics, immunotherapy and nanotechnology based approaches, the efficient management of even multidrug resistant tumors is also quite possible and several studies are currently under exhaustive clinical trials. The future work in the field of cancer therapy includes clearing the clinical trial pipeline into approved products followed by dedicated cancer prevention programs such as cancer vaccines.

References

1. International Agency for Research on Cancer (IARC), World Health Organization (WHO) (2012) Cancer fact sheets. In: Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer (IARC), World Health Organization (WHO), Lyon, France
2. Lippman SM, Hong WK (2002) Cancer prevention science and practice. *Cancer Res* 62:5119–5125, PMID: 12234971
3. Ghose T (2002) The current status of tumor targeting. In: Page M (ed) Tumor targeting in cancer therapy. Springer Science, New York, NY, pp 3–78
4. Poste G, Kirsh R (1983) Site-specific (targeted) drug delivery in cancer therapy. *Nat Biotechnol* 1:869–878. doi:[10.1038/nbt1283-869](https://doi.org/10.1038/nbt1283-869)
5. Parveen S, Sahoo SK (2008) Polymeric nanoparticles for cancer therapy. *J Drug Target* 16:108–123. doi:[10.1080/10611860701794353](https://doi.org/10.1080/10611860701794353)
6. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong K, Secomb TW (1996) Microvascular studies on the origins of perfusion-limited hypoxia. *Br J Cancer* 27(Suppl):S247–S251, PMID 8763890
7. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. *Mol Cancer Res* 4:61–70. doi:[10.1158/1541-7786.MCR-06-0002](https://doi.org/10.1158/1541-7786.MCR-06-0002)
8. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure – an obstacle in cancer therapy. *Nat Rev Cancer* 4:806–813. doi:[10.1038/nrc1456](https://doi.org/10.1038/nrc1456)
9. van den Berg AP, Wike-Hooley JL, van den Berg-Blok AE, van der Zee J, Reinhold HS (1982) Tumour pH in human mammary carcinoma. *Eur J Cancer Clin Oncol* 18:457–462. doi:[10.1016/0277-5379\(82\)90114-6](https://doi.org/10.1016/0277-5379(82)90114-6)
10. Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. *Cancer Res* 49:4373–4384, PMID: 2545340
11. Weinhouse S (1976) The Warburg hypothesis fifty years later. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol* 87:115–126, PMID: 136820
12. Yamagata M, Hasuda K, Stamato T, Tannock IF (1998) The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. *Br J Cancer* 77:1726–1731. doi:[10.1038/bjc.1998.289](https://doi.org/10.1038/bjc.1998.289)
13. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. *Cancer Treat Rev* 29:541–549. doi:[10.1016/S0305-7372\(03\)00106-3](https://doi.org/10.1016/S0305-7372(03)00106-3)

14. Griffiths JR, McIntyre DJ, Howe FA, Stubbs M (2001) Why are cancers acidic? A carrier-mediated diffusion model for H⁺ transport in the interstitial fluid. *Novartis Found Symp* 240:46–62, discussion 62–47, 152–153; PMID: 11727936
15. Narang AS, Varia S (2011) Role of tumor vascular architecture in drug delivery. *Adv Drug Deliv Rev* 63:640–658. doi:[10.1016/j.addr.2011.04.002](https://doi.org/10.1016/j.addr.2011.04.002)
16. Thanki K, Gangwal RP, Sangamwar AT, Jain S (2013) Oral delivery of anticancer drugs: challenges and opportunities. *J Control Release* 170:15–40. doi:[10.1016/j.jconrel.2013.04.020](https://doi.org/10.1016/j.jconrel.2013.04.020)
17. Weissig V, D'Souza GG (2010) *Organelle-specific pharmaceutical nanotechnology*. Wiley, Hoboken, NJ
18. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer Res* 46:6387–6392, PMID: 2946403
19. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* 95:4607–4612, PMID: 9539785
20. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK (2004) Pathology: cancer cells compress intratumour vessels. *Nature* 427:695. doi:[10.1038/427695a](https://doi.org/10.1038/427695a)
21. Rabanel JM, Aoun V, Elkin I, Mokhtar M, Hildgen P (2012) Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. *Curr Med Chem* 19:3070–3102. doi:[10.2174/092986712800784702](https://doi.org/10.2174/092986712800784702)
22. Nag OK, Awasthi V (2013) Surface engineering of liposomes for stealth behavior. *Pharmaceutics* 5:542–569. doi:[10.3390/pharmaceutics5040542](https://doi.org/10.3390/pharmaceutics5040542)
23. Salmaso S, Caliceti P (2013) Stealth properties to improve therapeutic efficacy of drug nanocarriers. *J Drug Deliv* 2013:374252. doi:[10.1155/2013/374252](https://doi.org/10.1155/2013/374252)
24. Allen TM, Hansen C, Rutledge J (1989) Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. *Biochim Biophys Acta* 981:27–35. doi:[10.1016/0005-2736\(89\)90078-3](https://doi.org/10.1016/0005-2736(89)90078-3)
25. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. *Proc Natl Acad Sci USA* 85:6949–6953, PMID: 3413128
26. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. *Int J Nanomedicine* 1:297–315, PMID: 17717971
27. Tirosh O, Barenholz Y, Katzhendler J, Prie A (1998) Hydration of polyethylene glycol-grafted liposomes. *Biophys J* 74:1371–1379. doi:[10.1016/S0006-3495\(98\)77849-X](https://doi.org/10.1016/S0006-3495(98)77849-X)
28. Lehtonen JY, Kinnunen PK (1995) Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes. *Biophys J* 68:525–535. doi:[10.1016/S0006-3495\(95\)80214-6](https://doi.org/10.1016/S0006-3495(95)80214-6)
29. Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. *Toxicology* 216:106–121. doi:[10.1016/j.tox.2005.07.023](https://doi.org/10.1016/j.tox.2005.07.023)
30. Yang Q, Ma Y, Zhao Y, She Z, Wang L, Li J, Wang C, Deng Y (2013) Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. *Int J Nanomedicine* 8:1257–1268. doi:[10.2147/IJN.S41701](https://doi.org/10.2147/IJN.S41701)
31. Herold DA, Keil K, Bruns DE (1989) Oxidation of polyethylene glycols by alcohol dehydrogenase. *Biochem Pharmacol* 38:73–76. doi:[10.1016/0006-2952\(89\)90151-2](https://doi.org/10.1016/0006-2952(89)90151-2)
32. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. *Drug Discov Today* 10:1451–1458. doi:[10.1016/S1359-6446\(05\)03575-0](https://doi.org/10.1016/S1359-6446(05)03575-0)
33. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. *Nat Rev Cancer* 2:750–763. doi:[10.1038/nrc903](https://doi.org/10.1038/nrc903)
34. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. *Expert Opin Pharmacother* 7:1041–1053. doi:[10.1517/14656566.7.8.1041](https://doi.org/10.1517/14656566.7.8.1041)
35. John TA, Vogel SM, Tirupathi C, Malik AB, Minshall RD (2003) Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. *Am J Physiol Lung Cell Mol Physiol* 284:L187–196. doi:[10.1152/ajplung.00152.2002](https://doi.org/10.1152/ajplung.00152.2002)

36. Minshall RD, Tiruppathi C, Vogel SM, Malik AB (2002) Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. *Histochem Cell Biol* 117:105–112. doi:[10.1007/s00418-001-0367-x](https://doi.org/10.1007/s00418-001-0367-x)
37. Kumagai AK, Eisenberg JB, Pardridge WM (1987) Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. *J Biol Chem* 262:15214–15219. PMID: 2959663
38. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clin Cancer Res* 12:1317–1324. doi:[10.1158/1078-0432.CCR-05-1634](https://doi.org/10.1158/1078-0432.CCR-05-1634)
39. Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for cancer tissue. *Expert Opin Drug Deliv* 6:285–304. doi:[10.1517/17425240902780166](https://doi.org/10.1517/17425240902780166)
40. Vasir JK, Labhasetwar V (2005) Targeted drug delivery in cancer therapy. *Technol Cancer Res Treat* 4:363–374. PMID: 16029056
41. Jain S, Mathur R, Das M, Swarnakar NK, Mishra AK (2011) Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles. *Nanomedicine (Lond)* 6:1733–1754. doi:[10.2217/nnm.11.53](https://doi.org/10.2217/nnm.11.53)
42. Das M, Bandyopadhyay D, Mishra D, Datir S, Dhak P, Jain S, Maiti TK, Basak A, Pramanik P (2011) “Clickable”, trifunctional magnetite nanoparticles and their chemoselective bio-functionalization. *Bioconjug Chem* 22:1181–1193. doi:[10.1021/bc2000484](https://doi.org/10.1021/bc2000484)
43. Das M, Datir SR, Singh RP, Jain S (2013) Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic acid-multiwalled carbon nanotube conjugate. *Mol Pharm* 10:2543–2557. doi:[10.1021/mp300701e](https://doi.org/10.1021/mp300701e)
44. Lu YJ, Wei KC, Ma CC, Yang SY, Chen JP (2012) Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. *Colloids Surf B: Biointerfaces* 89:1–9. doi:[10.1016/j.colsurfb.2011.08.001](https://doi.org/10.1016/j.colsurfb.2011.08.001)
45. Li L, Yang Q, Zhou Z, Zhong J, Huang Y (2014) Doxorubicin-loaded, charge reversible, folate modified HEMA copolymer conjugates for active cancer cell targeting. *Biomaterials* 35:5171–5187. doi:[10.1016/j.biomaterials.2014.03.027](https://doi.org/10.1016/j.biomaterials.2014.03.027)
46. Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G (2013) Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. *Nanomedicine* 8:875–890. doi:[10.2217/nnm.12.137](https://doi.org/10.2217/nnm.12.137)
47. Hong G, Yuan R, Liang B, Shen J, Yang X, Shuai X (2008) Folate-functionalized polymeric micelle as hepatic carcinoma-targeted, MRI-ultrasensitive delivery system of antitumor drugs. *Biomed Microdevices* 10:693–700. doi:[10.1007/s10544-008-9180-9](https://doi.org/10.1007/s10544-008-9180-9)
48. Tyagi N, Ghosh PC (2011) Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes. *Eur J Pharm Sci* 43:343–353. doi:[10.1016/j.ejps.2011.05.010](https://doi.org/10.1016/j.ejps.2011.05.010)
49. Lale SV, GA R, Aravind A, Kumar DS, Koul V (2014) AS1411 Aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy. *Biomacromolecules* 15:1737–1752. doi:[10.1021/bm5001263](https://doi.org/10.1021/bm5001263)
50. El-Gogary RI, Rubio N, Wang JT, Al-Jamal WT, Bourgognon M, Kafa H, Naeem M, Klippstein R, Abbate V, Leroux F, Bals S, Van Tendeloo G, Kamel AO, Awad GA, Mortada ND, Al-Jamal KT (2014) Polyethylene glycol conjugated polymeric nanocapsules for targeted delivery of quercetin to folate-expressing cancer cells in vitro and in vivo. *ACS Nano* 8:1384–1401. doi:[10.1021/nn405155b](https://doi.org/10.1021/nn405155b)
51. Tavassolian F, Kamalinia G, Rouhani H, Amini M, Ostad SN, Khoshayand MR, Atyabi F, Tehrani MR, Dinarvand R (2014) Targeted poly (L-gamma-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells. *Int J Pharm* 467:123–138. doi:[10.1016/j.ijpharm.2014.03.033](https://doi.org/10.1016/j.ijpharm.2014.03.033)

52. Nair BP, Vaikkath D, Nair PD (2014) Polyhedral oligomeric silsesquioxane-F68 hybrid vesicles for folate receptor targeted anti-cancer drug delivery. *Langmuir* 30:340–347. doi:[10.1021/la4036997](https://doi.org/10.1021/la4036997)
53. Chen YC, Chiang CF, Chen LF, Liang PC, Hsieh WY, Lin WL (2014) Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. *Biomaterials* 35:4066–4081. doi:[10.1016/j.biomaterials.2014.01.042](https://doi.org/10.1016/j.biomaterials.2014.01.042)
54. Dowlati A, Loo M, Bury T, Fillet G, Beguin Y (1997) Soluble and cell-associated transferrin receptor in lung cancer. *Br J Cancer* 75:1802–1806. doi:[10.1038/bjc.1997.307](https://doi.org/10.1038/bjc.1997.307)
55. Gosk S, Vermehren C, Storm G, Moos T (2004) Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. *J Cereb Blood Flow Metab* 24:1193–1204. doi:[10.1097/01.WCB.0000135592.28823.47](https://doi.org/10.1097/01.WCB.0000135592.28823.47)
56. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. *Mol Pharm* 2:373–383. doi:[10.1021/mp050032z](https://doi.org/10.1021/mp050032z)
57. Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. *Int J Cancer* 112:335–340. doi:[10.1002/ijc.20405](https://doi.org/10.1002/ijc.20405)
58. Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI (2011) Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. *Small* 7:1816–1826. doi:[10.1002/sml.201002300](https://doi.org/10.1002/sml.201002300)
59. Kim TH, Jo YG, Jiang HH, Lim SM, Youn YS, Lee S, Chen X, Byun Y, Lee KC (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. *J Control Release* 162:422–428. doi:[10.1016/j.jconrel.2012.07.021](https://doi.org/10.1016/j.jconrel.2012.07.021)
60. Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt C (2012) Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. *J Aerosol Med Pulm Drug Deliv* 25:310–318. doi:[10.1089/jamp.2011.0928](https://doi.org/10.1089/jamp.2011.0928)
61. Liu G, Shen H, Mao J, Zhang L, Jiang Z, Sun T, Lan Q, Zhang Z (2013) Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. *ACS Appl Mater Interfaces* 5:6909–6914. doi:[10.1021/am402128s](https://doi.org/10.1021/am402128s)
62. Neves S, Faneca H, Bertin S, Konopka K, Duzgunes N, Pierrefite-Carle V, Simoes S, Pedrosa de Lima MC (2009) Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the anti-tumoral response. *Cancer Gene Ther* 16:91–101. doi:[10.1038/cgt.2008.60](https://doi.org/10.1038/cgt.2008.60)
63. Vaidya B, Vyas SP (2012) Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization. *J Drug Target* 20:372–380. doi:[10.3109/1061186X.2012.662687](https://doi.org/10.3109/1061186X.2012.662687)
64. Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP (2014) Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. *Pharm Res* 1–8. doi: [10.1007/s11095-013-1295-x](https://doi.org/10.1007/s11095-013-1295-x)
65. Yhee JY, Lee SJ, Lee S, Song S, Min HS, Kang SW, Son S, Jeong SY, Kwon IC, Kim SH, Kim K (2013) Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice. *Bioconjug Chem* 24:1850–1860. doi:[10.1021/bc400226b](https://doi.org/10.1021/bc400226b)
66. Huang Y, He L, Liu W, Fan C, Zheng W, Wong Y-S, Chen T (2013) Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. *Biomaterials* 34:7106–7116. doi:[10.1016/j.biomaterials.2013.04.067](https://doi.org/10.1016/j.biomaterials.2013.04.067)
67. Bies C, Lehr CM, Woodley JF (2004) Lectin-mediated drug targeting: history and applications. *Adv Drug Deliv Rev* 56:425–435. doi:[10.1016/j.addr.2003.10.030](https://doi.org/10.1016/j.addr.2003.10.030)
68. Baenziger JU, Maynard Y (1980) Human hepatic lectin. Physicochemical properties and specificity. *J Biol Chem* 255:4607–4613, PMID: 7372599
69. Duncan R (2003) The dawning era of polymer therapeutics. *Nat Rev Drug Discov* 2:347–360. doi:[10.1038/nrd1088](https://doi.org/10.1038/nrd1088)
70. Yu HY, Lin JH (2000) Intracellular delivery of membrane-impermeable hydrophilic molecules to a hepatoblastoma cell line by asialoglycoprotein-labeled liposomes. *J Formos Med Assoc* 99:936–941, PMID: 11155748

71. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP (2004) Liposomes modified with cyclic RGD peptide for tumor targeting. *J Drug Target* 12:257–264. doi:[10.1080/10611860410001728040](https://doi.org/10.1080/10611860410001728040)
72. Aina OH, Sroka TC, Chen ML, Lam KS (2002) Therapeutic cancer targeting peptides. *Biopolymers* 66:184–199. doi:[10.1002/bip.10257](https://doi.org/10.1002/bip.10257)
73. Torchilin VP (2000) Drug targeting. *Eur J Pharm Sci* 11(Suppl 2):S81–91. doi:[10.1016/S0928-0987\(00\)00166-4](https://doi.org/10.1016/S0928-0987(00)00166-4)
74. Hussein GA, Diaz de la Rosa MA, Gabuji T, Zeng Y, Christensen DA, Pitt WG (2007) Release of doxorubicin from unstabilized and stabilized micelles under the action of ultrasound. *J Nanosci Nanotechnol* 7:1028–1033. doi:[10.1166/jnn.2007.218](https://doi.org/10.1166/jnn.2007.218)
75. Knights CD, Pestell RG (2008) The cell cycle: therapeutic targeting of cell cycle regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K (eds) *Molecular targeting in oncology*. Humana, Totowa, NJ
76. Liu MC, Marshall JL, Pestell RG (2004) Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. *Curr Cancer Drug Targets* 4:403–424. doi:[10.2174/1568009043332907](https://doi.org/10.2174/1568009043332907)
77. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, Miranda M, Krig S, Garbe J, Stampfer M, Yaswen P, Gray JW, Lockett SJ (2004) In situ analyses of genome instability in breast cancer. *Nat Genet* 36:984–988. doi:[10.1038/ng1409](https://doi.org/10.1038/ng1409)
78. Deshpande A, Sicinski P, Hinds PW (2005) Cyclins and cdks in development and cancer: a perspective. *Oncogene* 24:2909–2915. doi:[10.1038/sj.onc.1208618](https://doi.org/10.1038/sj.onc.1208618)
79. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johansson O, Olsson H, Sauter G (2001) Gene-expression profiles in hereditary breast cancer. *N Engl J Med* 344:539–548. doi:[10.1056/NEJM20010223440801](https://doi.org/10.1056/NEJM20010223440801)
80. Dobbelsstein M, Moll U (2014) Targeting tumour-supportive cellular machineries in anticancer drug development. *Nat Rev Drug Discov* 13:179–196. doi:[10.1038/nrd4201](https://doi.org/10.1038/nrd4201)
81. Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D, Robison LL (2011) Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol* 29:3056–3064. doi:[10.1200/JCO.2011.34.6585](https://doi.org/10.1200/JCO.2011.34.6585)
82. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 97:1354–1365. doi:[10.1093/jnci/dji278](https://doi.org/10.1093/jnci/dji278)
83. De Koning P, Neijt JP, Jennekens FG, Gispen WH (1987) Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. *Toxicol Appl Pharmacol* 89:81–87. doi:[10.1016/0041-008X\(87\)90178-5](https://doi.org/10.1016/0041-008X(87)90178-5)
84. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, Doetsch PW (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS One* 8:e81162. doi:[10.1371/journal.pone.0081162](https://doi.org/10.1371/journal.pone.0081162)
85. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell* 136:823–837. doi:[10.1016/j.cell.2009.02.024](https://doi.org/10.1016/j.cell.2009.02.024)
86. Greenman C, Stephens P, Smith R, Dalgleish GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF,

- Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR (2007) Patterns of somatic mutation in human cancer genomes. *Nature* 446:153–158. doi:[10.1038/nature05610](https://doi.org/10.1038/nature05610)
87. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nat Rev Drug Discov* 1:493–502. doi:[10.1038/nrd839](https://doi.org/10.1038/nrd839)
88. Ashwell S, Zabludoff S (2008) DNA damage detection and repair pathways—recent advances with inhibitors of checkpoint kinases in cancer therapy. *Clin Cancer Res* 14:4032–4037. doi:[10.1158/1078-0432.CCR-07-5138](https://doi.org/10.1158/1078-0432.CCR-07-5138)
89. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. *Cancer Cell* 12:9–22. doi:[10.1016/j.ccr.2007.05.008](https://doi.org/10.1016/j.ccr.2007.05.008)
90. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. *Nat Rev Mol Cell Biol* 11:515–528. doi:[10.1038/nrm2918](https://doi.org/10.1038/nrm2918)
91. Stadtman ER (2001) Protein oxidation in aging and age-related diseases. *Ann N Y Acad Sci* 928:22–38. doi:[10.1111/j.1749-6632.2001.tb05632.x](https://doi.org/10.1111/j.1749-6632.2001.tb05632.x)
92. Soga S, Akinaga S, Shiotsu Y (2013) Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. *Curr Pharm Des* 19:366–376. doi:[10.2174/1381612811306030366](https://doi.org/10.2174/1381612811306030366)
93. Shen M, Ping Dou Q (2013) Proteasome inhibition as a novel strategy for cancer treatment. In: Johnson DE (ed) *Cell death signaling in cancer biology and treatment*. Springer Sciences, New York, NY, pp 303–329
94. Groll M, Berkers CR, Ploegh HL, Ova H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. *Structure* 14:451–456. doi:[10.1016/j.str.2005.11.019](https://doi.org/10.1016/j.str.2005.11.019)
95. D’Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. *Nat Med* 17:1636–1640. doi:[10.1038/nm.2536](https://doi.org/10.1038/nm.2536)
96. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. *Nature* 467:179–184. doi:[10.1038/nature09299](https://doi.org/10.1038/nature09299)
97. Ceccarelli DF, Tang X, Pelletier B, Orlicky S, Xie W, Plantevin V, Neculai D, Chou YC, Ogunjimi A, Al-Hakim A, Varelas X, Koszela J, Wasney GA, Vedadi M, Dhe-Paganon S, Cox S, Xu S, Lopez-Girona A, Mercurio F, Wrana J, Durocher D, Meloche S, Webb DR, Tyers M, Sicheri F (2011) An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. *Cell* 145:1075–1087. doi:[10.1016/j.cell.2011.05.039](https://doi.org/10.1016/j.cell.2011.05.039)
98. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 458:732–736. doi:[10.1038/nature07884](https://doi.org/10.1038/nature07884)
99. Deshpande AJ, Bradner J, Armstrong SA (2012) Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. *Trends Immunol* 33:563–570. doi:[10.1016/j.it.2012.06.002](https://doi.org/10.1016/j.it.2012.06.002)
100. Chi P, Allis CD, Wang GG (2010) Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. *Nat Rev Cancer* 10:457–469. doi:[10.1038/nrc2876](https://doi.org/10.1038/nrc2876)
101. Kubota Y (2012) Tumor angiogenesis and anti-angiogenic therapy. *Keio J Med* 61:47–56. doi:[10.2302/kjm.61.47](https://doi.org/10.2302/kjm.61.47)
102. Risau W (1997) Mechanisms of angiogenesis. *Nature* 386:671–674. doi:[10.1038/386671a0](https://doi.org/10.1038/386671a0)
103. Bikfalvi A, Bicknell R (2002) Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. *Trends Pharmacol Sci* 23:576–582. doi:[10.1016/S0165-6147\(02\)02109-0](https://doi.org/10.1016/S0165-6147(02)02109-0)
104. Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. *Annu Rev Cell Dev Biol* 27:563–584. doi:[10.1146/annurev-cellbio-092910-154002](https://doi.org/10.1146/annurev-cellbio-092910-154002)

105. Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2008) A dialogue between the hypoxia-inducible factor and the tumor microenvironment. *Cancer Microenviron* 1:53–68. doi:[10.1007/s12307-008-0006-3](https://doi.org/10.1007/s12307-008-0006-3)
106. Nagy JA, Dvorak AM, Dvorak HF (2007) VEGF-A and the induction of pathological angiogenesis. *Annu Rev Pathol* 2:251–275. doi:[10.1146/annurev.pathol.2.010506.134925](https://doi.org/10.1146/annurev.pathol.2.010506.134925)
107. Hendrix MJ, Sefter EA, Hess AR, Sefter RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. *Nat Rev Cancer* 3:411–421. doi:[10.1038/nrc1092](https://doi.org/10.1038/nrc1092)
108. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. *Nat Rev Mol Cell Biol* 8:464–478. doi:[10.1038/nrm2183](https://doi.org/10.1038/nrm2183)
109. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. *Cancer Lett* 320:130–137. doi:[10.1016/j.canlet.2012.03.008](https://doi.org/10.1016/j.canlet.2012.03.008)
110. Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y (2013) Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. *Med Oncol* 30:752. doi:[10.1007/s12032-013-0752-z](https://doi.org/10.1007/s12032-013-0752-z)
111. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol* 30:3499–3506. doi:[10.1200/JCO.2012.42.8201](https://doi.org/10.1200/JCO.2012.42.8201)
112. Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST (2013) Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. *Clin Cancer Res* 19:6943–6956. doi:[10.1158/1078-0432.CCR-13-1637](https://doi.org/10.1158/1078-0432.CCR-13-1637)
113. Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. *Angiogenesis*. doi:[10.1007/s10456-014-9420-y](https://doi.org/10.1007/s10456-014-9420-y)
114. Henkin J, Volpert OV (2011) Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. *Expert Opin Ther Targets* 15:1369–1386. doi:[10.1517/14728222.2011.640319](https://doi.org/10.1517/14728222.2011.640319)
115. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res* 60:1878–1886, PMID: 10766175
116. Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K (2006) The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. *Cancer Chemother Pharmacol* 58:354–360. doi:[10.1007/s00280-005-0163-8](https://doi.org/10.1007/s00280-005-0163-8)
117. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV (2005) Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. *Clin Cancer Res* 11:6678–6685. doi:[10.1158/1078-0432.CCR-05-0621](https://doi.org/10.1158/1078-0432.CCR-05-0621)
118. Streit M, Stephen AE, Hawighorst T, Matsuda K, Lange-Asschenfeldt B, Brown LF, Vacanti JP, Detmar M (2002) Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. *Cancer Res* 62:2004–2012, PMID: 11929817
119. Butler GS, Overall CM (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. *Nat Rev Drug Discov* 8:935–948. doi:[10.1038/nrd2945](https://doi.org/10.1038/nrd2945)
120. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. *Tumour Biol* 34:2041–2051. doi:[10.1007/s13277-013-0842-8](https://doi.org/10.1007/s13277-013-0842-8)
121. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC (2006) Drug insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery. *Nat Clin Pract Oncol* 3:682–692. doi:[10.1038/nncponc0663](https://doi.org/10.1038/nncponc0663)
122. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. *Cancer Res* 57:1829–1834, PMID: 9157969

123. Zhou S, Kestell P, Baguley BC, Paxton JW (2002) 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. *Invest New Drugs* 20:281–295. doi:[10.1023/A:1016215015530](https://doi.org/10.1023/A:1016215015530)
124. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 14:1014–1022. doi:[10.1038/ni.2703](https://doi.org/10.1038/ni.2703)
125. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. *Cancer Cell* 23:516–526. doi:[10.1016/j.ccr.2013.03.018](https://doi.org/10.1016/j.ccr.2013.03.018)
126. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Clifton P, Tykseen E, Samuels Y, Rosenberg SA (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 19:747–752. doi:[10.1038/nm.3161](https://doi.org/10.1038/nm.3161)
127. Goldenberg DM (1993) Monoclonal antibodies in cancer detection and therapy. *Am J Med* 94:297–312. doi:[10.1016/0002-9343\(93\)90062-T](https://doi.org/10.1016/0002-9343(93)90062-T)
128. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. *Nat Rev Cancer* 1:118–129. doi:[10.1038/35101072](https://doi.org/10.1038/35101072)
129. Monoclonal antibody therapy (2014). http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy. Accessed Mar 2014.
130. Sharkey RM, Goldenberg DM (2011) Cancer radioimmunotherapy. *Immunotherapy* 3:349–370. doi:[10.2217/imt.10.114](https://doi.org/10.2217/imt.10.114)
131. Pressman D, Korngold L (1953) The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. *Cancer* 6:619–623, PMID: 13042784
132. DeNardo SJ, DeNardo GL, O’Grady LF, Macey DJ, Mills SL, Epstein AL, Peng JS, McGahan JP (1987) Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. *Int J Biol Markers* 2:49–53, PMID: 3501448
133. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA et al (1989) Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. *J Clin Oncol* 7:1027–1038, PMID: 2666588
134. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM et al (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. *N Engl J Med* 329:459–465. doi:[10.1056/NEJM199308123290703](https://doi.org/10.1056/NEJM199308123290703)
135. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. *J Nucl Med* 43:693–713, PMID: 11994535
136. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial watch: anticancer radioimmunotherapy. *Oncoimmunology* 2:e25595. doi:[10.4161/onci.25595](https://doi.org/10.4161/onci.25595)
137. www.clinicaltrials.gov. Accessed in Mar 2014
138. Almqvist Y, Orlova A, Sjöström A, Jensen HJ, Lundqvist H, Sundin A, Tolmachev V (2005) In vitro characterization of 211At-labeled antibody A33-a potential therapeutic agent against metastatic colorectal carcinoma. *Cancer Biother Radiopharm* 20:514–523. doi:[10.1089/cbr.2005.20.514](https://doi.org/10.1089/cbr.2005.20.514)
139. Pickhard A, Piontek G, Seidl C, Kopping S, Blechert B, Misslbeck M, Brockhoff G, Bruchertseifer F, Morgenstern A, Essler M (2014) (2)(1)(3)Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. *Nucl Med Biol* 41:68–76. doi:[10.1016/j.nucmedbio.2013.09.010](https://doi.org/10.1016/j.nucmedbio.2013.09.010)
140. Qu C, Li Y, Song Y, Rizvi S, Raja C, Zhang D, Samra J, Smith R, Perkins A, Apostolidis C (2004) MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate. *Br J Cancer* 91:2086–2093. doi:[10.1038/sj.bjc.6602232](https://doi.org/10.1038/sj.bjc.6602232)
141. Zhang DY, Li Y, Rizvi SMA, Qu C, Kearsley J, Allen BJ (2005) Cytotoxicity of breast cancer cells overexpressing HER2/neu by ²¹³Bi-Herceptin radioimmunoconjugate. *Cancer Lett* 218:181–190. doi:[10.1016/j.canlet.2004.07.050](https://doi.org/10.1016/j.canlet.2004.07.050)

142. Li Y, Song E, Abbas Rizvi SM, Power CA, Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ, Russell PJ (2009) Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. *Clin Cancer Res* 15:865–875. doi:[10.1158/1078-0432.CCR-08-1203](https://doi.org/10.1158/1078-0432.CCR-08-1203)
143. Pavlinkova G, Booth BJ, Batra SK, Colcher D (1999) Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. *Clin Cancer Res* 5:2613–2619, PMID: 10499640
144. Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM (2007) 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1. *Eur J Nucl Med Mol Imaging* 34:368–377. doi:[10.1007/s00259-006-0189-0](https://doi.org/10.1007/s00259-006-0189-0)
145. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. *J Nucl Med* 45:327–337, PMID: 14960657
146. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM (1997) Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. *Int J Cancer* 72:477–485. doi:[10.1002/\(SICI\)1097-0215\(19970729\)72:3<477::AID-IJC16>3.0.CO;2-9](https://doi.org/10.1002/(SICI)1097-0215(19970729)72:3<477::AID-IJC16>3.0.CO;2-9)
147. Cornelissen B, Darbar S, Kersemans V, Allen D, Falzone N, Barbeau J, Smart S, Vallis KA (2012) Amplification of DNA damage by a gammaH2AX-targeted radiopharmaceutical. *Nucl Med Biol* 39:1142–1151. doi:[10.1016/j.nucmedbio.2012.06.001](https://doi.org/10.1016/j.nucmedbio.2012.06.001)
148. Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G (2006) Pharmacokinetics and tumor localization of 111In-labeled HuCC49ΔCH2 in BALB/c mice and athymic murine colon carcinoma xenograft. *Cancer Biother Radiopharm* 21:106–116. doi:[10.1089/cbr.2006.21.106](https://doi.org/10.1089/cbr.2006.21.106)
149. Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM (2008) Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. *Nucl Med Biol* 35:101–110. doi:[10.1016/j.nucmedbio.2007.09.007](https://doi.org/10.1016/j.nucmedbio.2007.09.007)
150. Liu P, Boyle AJ, Lu Y, Reilly RM, Winnik MA (2012) Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment. *Biomacromolecules* 13:2831–2842. doi:[10.1021/bm300843u](https://doi.org/10.1021/bm300843u)
151. Sandstrom K, Nestor M, Ekberg T, Engstrom M, Anniko M, Lundqvist H (2008) Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody. *Tumour Biol* 29:137–144. doi:[10.1159/000143399](https://doi.org/10.1159/000143399)
152. Price EW, Zeglis BM, Cawthray JF, Ramogida CF, Ramos N, Lewis JS, Adam MJ, Orvig C (2013) H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. *J Am Chem Soc* 135:12707–12721. doi:[10.1021/ja4049493](https://doi.org/10.1021/ja4049493)
153. Tempero M, Lechner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D (2000) High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. *Clin Cancer Res* 6:3095–3102, PMID: 10955789
154. Fischer E, Grunberg J, Cohrs S, Hohn A, Waldner-Knogler K, Jeger S, Zimmermann K, Novak-Hofer I, Schibli R (2012) L1-CAM-targeted antibody therapy and (177) Lu-radioimmunotherapy of disseminated ovarian cancer. *Int J Cancer* 130:2715–2721. doi:[10.1002/ijc.26321](https://doi.org/10.1002/ijc.26321)
155. Nilsson R, Eriksson SE, Sjogren HO, Tennvall J (2011) Different toxicity profiles for drug-versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model. *Acta Oncol* 50:711–718. doi:[10.3109/0284186X.2010.547215](https://doi.org/10.3109/0284186X.2010.547215)
156. Schneider N, Lobaugh N, Tan Z, Sandwall P, Chen P, Glover S, Cui L, Murry M, Dong Z, Torgue J (2013) Biodistribution of 212Pb conjugated trastuzumab in mice. *J Radioanal Nucl Chem* 296:75–81. doi:[10.1007/s10967-012-2243-7](https://doi.org/10.1007/s10967-012-2243-7)
157. Mohsin H, Jia F, Sivaguru G, Hudson MJ, Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J (2006) Radiolanthanide-labeled monoclonal antibody CC49 for

- radioimmunotherapy of cancer: biological comparison of DOTA conjugates and ^{149}Pm , ^{166}Ho , and ^{177}Lu . *Bioconjug Chem* 17:485–492. doi:[10.1021/bc0502356](https://doi.org/10.1021/bc0502356)
158. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA (2000) Safety and biodistribution of $^{99\text{m}}\text{Tc}$ -labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. *Clin Cancer Res* 6:3046–3055, PMID: 10955783
 159. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland OS, Press OW, Larsen RH (2007) Targeted cancer therapy with a novel low-dose rate alpha-emitting radio-immunoconjugate. *Blood* 110:2049–2056. doi:[10.1182/blood-2007-01-066803](https://doi.org/10.1182/blood-2007-01-066803)
 160. Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J (2012) Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting ^{227}Th -DOTA-p-benzyl-trastuzumab. *PLoS One* 7:e42345. doi:[10.1371/journal.pone.0042345](https://doi.org/10.1371/journal.pone.0042345)
 161. Maraveyas A, Snook D, Hird V, Kosmas C, Meares CF, Lambert HE, Epenetos AA (1994) Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. *Cancer* 73:1067–1075, PMID: 8306249
 162. Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q (2013) Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. *J Control Release* 172:1020–1034. doi:[10.1016/j.jconrel.2013.10.012](https://doi.org/10.1016/j.jconrel.2013.10.012)
 163. Kitson SL, Cuccurullo V, Moody TS, Mansi L (2013) Radionuclide antibody-conjugates, a targeted therapy towards cancer. *Curr Radiopharm* 6:57–71. doi:[10.2174/1874471011306020001](https://doi.org/10.2174/1874471011306020001)
 164. Zhang L, Chen H, Wang L, Liu T, Yeh J, Lu G, Yang L, Mao H (2010) Delivery of therapeutic radioisotopes using nanoparticle platforms: potential benefit in systemic radiation therapy. *Nanotechnol Sci Appl* 3:159–170. doi:[10.2147/NSA.S7462](https://doi.org/10.2147/NSA.S7462)
 165. Barrett T, Ravizzini G, Choyke PL, Kobayashi H (2009) Dendrimers in medical nanotechnology. *IEEE Eng Med Biol Mag* 28:12–22. doi:[10.1109/MEMB.2008.931012](https://doi.org/10.1109/MEMB.2008.931012)
 166. Veisheh O, Kievit FM, Ellenbogen RG, Zhang M (2011) Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. *Adv Drug Deliv Rev* 63:582–596. doi:[10.1016/j.addr.2011.01.010](https://doi.org/10.1016/j.addr.2011.01.010)
 167. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated ^{90}Y -labeled nanoparticles. *Int J Radiat Oncol Biol Phys* 58:1215–1227. doi:[10.1016/j.ijrobp.2003.10.057](https://doi.org/10.1016/j.ijrobp.2003.10.057)
 168. Belhaj-Tayeb H, Briane D, Vergote J, Kothan S, Leger G, Bendada SE, Tofighi M, Tamgac F, Cao A, Moretti JL (2003) In vitro and in vivo study of $^{99\text{m}}\text{Tc}$ -MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging. *Eur J Nucl Med Mol Imaging* 30:502–509. doi:[10.1007/s00259-002-1038-4](https://doi.org/10.1007/s00259-002-1038-4)
 169. Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW (1999) Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. *Bioconjug Chem* 10:103–111. doi:[10.1021/bc980091d](https://doi.org/10.1021/bc980091d)
 170. Torchilin VP (2002) PEG based micelles as carriers of contrast agents for different imaging modalities. *Adv Drug Deliv Rev* 54:235–252. doi:[10.1016/S0169-409X\(02\)00019-4](https://doi.org/10.1016/S0169-409X(02)00019-4)
 171. Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E, Gao X, Clanton J (2003) Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. *Cancer Cell* 3:63–74. doi:[10.1016/S1535-6108\(02\)00238-6](https://doi.org/10.1016/S1535-6108(02)00238-6)
 172. Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Gulyas G, Athey P, Scott MJ, Wickline SA, Lanza GM (2007) Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted ^{111}In nanoparticles. *Int J Cancer* 120:1951–1957. doi:[10.1002/ijc.22581](https://doi.org/10.1002/ijc.22581)
 173. Chang YJ, Chang CH, Yu CY, Chang TJ, Chen LC, Chen MH, Lee TW, Ting G (2010) Therapeutic efficacy and microSPECT/CT imaging of ^{188}Re -DXR-liposome in a C26 murine colon carcinoma solid tumor model. *Nucl Med Biol* 37:95–104. doi:[10.1016/j.nucmedbio.2009.08.006](https://doi.org/10.1016/j.nucmedbio.2009.08.006)

174. Vicente S, Goins BA, Sanchez A, Alonso MJ, Phillips WT (2014) Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules. *Vaccine* 32:1685–1692. doi:[10.1016/j.vaccine.2014.01.059](https://doi.org/10.1016/j.vaccine.2014.01.059)
175. Chen J, Wu H, Han D, Xie C (2006) Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. *Cancer Lett* 231:169–175. doi:[10.1016/j.canlet.2005.01.024](https://doi.org/10.1016/j.canlet.2005.01.024)
176. Wu H, Wang J, Wang Z, Fisher DR, Lin Y (2008) Apoferritin-templated yttrium phosphate nanoparticle conjugates for radioimmunotherapy of cancers. *J Nanosci Nanotechnol* 8:2316–2322, PMID: 18572643
177. Woodward JD, Kennel SJ, Mirzadeh S, Dai S, Wall JS, Richey T, Avenell J, Rondoni AJ (2007) In vivo SPECT/CT imaging and biodistribution using radioactive Cd125mTe/ZnS nanoparticles. *Nanotechnology* 18:175103. doi:[10.1088/0957-4484/18/17/175103](https://doi.org/10.1088/0957-4484/18/17/175103)
178. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H (2007) In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. *Nat Nanotechnol* 2:47–52. doi:[10.1038/nnano.2006.170](https://doi.org/10.1038/nnano.2006.170)
179. Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S (2014) Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivasculature alpha-particle therapy of cancer. *J Nucl Med* 55:107–114. doi:[10.2967/jnumed.113.125476](https://doi.org/10.2967/jnumed.113.125476)
180. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I (2014) Immunotoxins for leukemia. *Blood*. doi:[10.1182/blood-2014-01-492256](https://doi.org/10.1182/blood-2014-01-492256)
181. Atignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. *Toxins (Basel)* 5:1486–1502. doi:[10.3390/toxins5081486](https://doi.org/10.3390/toxins5081486)
182. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin difitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol* 19:376–388, PMID: 11208829
183. Jansen FK, Bourrie B, Casellas P, Dussossoy D, Gros O, Vic P, Vidal H, Gros P (1988) Toxin selection and modification: utilization of the A chain of ricin. *Cancer Treat Res* 37:97–111. doi:[10.1007/978-1-4613-1083-9_7](https://doi.org/10.1007/978-1-4613-1083-9_7)
184. Hudson TH, Neville DM Jr (1988) Enhancement of immunotoxin action: manipulation of the cellular routing of proteins. *Cancer Treat Res* 37:371–389. doi:[10.1007/978-1-4613-1083-9_20](https://doi.org/10.1007/978-1-4613-1083-9_20)
185. Casellas P, Jansen FK (1988) Immunotoxin enhancers. *Cancer Treat Res* 37:351–369. doi:[10.1007/978-1-4613-1083-9_19](https://doi.org/10.1007/978-1-4613-1083-9_19)
186. Kantarjian H, Thomas D, Wayne AS, O'Brien S (2012) Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. *J Clin Oncol* 30:3876–3883. doi:[10.1200/JCO.2012.41.6768](https://doi.org/10.1200/JCO.2012.41.6768)
187. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA (2000) A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. *Clin Cancer Res* 6:1302–1313, PMID: 10778955
188. Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM (1999) A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. *Clin Cancer Res* 5:2392–2398, PMID: 10499609
189. Vitetta ES (2000) Immunotoxins and vascular leak syndrome. *Cancer J* 6(Suppl 3):S218–224, PMID: 10874491
190. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M (1997) Characterization of vascular leak syndrome induced by the toxin component of *Pseudomonas* exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. *Clin Cancer Res* 3:339–345, PMID: 9815690

191. Hu RG, Zhai QW, He WJ, Mei L, Liu WY (2002) Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. *Int J Biochem Cell Biol* 34:396–402. doi:[10.1016/S1357-2725\(01\)00128-5](https://doi.org/10.1016/S1357-2725(01)00128-5)
192. Oraki Kohshour M, Mirzaie S, Zeinali M, Amin M, Said Hakhamaneshi M, Jalaili A, Mosaveri N, Jamalani M (2014) Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. *Chem Biol Drug Des* 83:259–265. doi:[10.1111/cbdd.12244](https://doi.org/10.1111/cbdd.12244)
193. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. *Cancer Res* 56:1324–1330, PMID: 8640821
194. Selbo PK, Kaalhus O, Sivam G, Berg K (2001) 5-Aminolevulinic acid-based photochemical internalization of the immunotoxin MOC31-gelonin generates synergistic cytotoxic effects in vitro. *Photochem Photobiol* 74:303–310. doi:[10.1562/0031-8655\(2001\)0740303AABPIO2.0.CO2](https://doi.org/10.1562/0031-8655(2001)0740303AABPIO2.0.CO2)
195. Schiffer S, Letzian S, Jost E, Mladenov R, Hristodorov D, Huhn M, Fischer R, Barth S, Thepen T (2013) Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22 (scFv) against leukemic cells. *Cancer Lett* 341:178–185. doi:[10.1016/j.canlet.2013.08.005](https://doi.org/10.1016/j.canlet.2013.08.005)
196. Bergelt S, Frost S, Lilie H (2009) Listeriolysin O as cytotoxic component of an immunotoxin. *Protein Sci* 18:1210–1220. doi:[10.1002/pro.130](https://doi.org/10.1002/pro.130)
197. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I (2000) Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. *J Immunother* 23:473–479. doi:[10.1097/00002371-200007000-00011](https://doi.org/10.1097/00002371-200007000-00011)
198. Bruell D, Stocker M, Huhn M, Redding N, Kupper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R, Barth S (2003) The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. *Int J Oncol* 23:1179–1186, PMID: 12964002
199. Park JH, Kwon HW, Chung HK, Kim IH, Ahn K, Choi EJ, Pastan I, Choe M (2001) A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains. *Mol Cells* 12:398–402, PMID: 11804341
200. Beers R, Chowdhury P, Bigner D, Pastan I (2000) Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. *Clin Cancer Res* 6:2835–2843, PMID: 10914732
201. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. *Clin Cancer Res* 8:995–1002, PMID: 11948105
202. Akamatsu Y, Murphy JC, Nolan KF, Thomas P, Kreitman RJ, Leung SO, Junghans RP (1998) A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. *Clin Cancer Res* 4:2825–2832, PMID: 9829749
203. Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I (2012) A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. *Protein Eng Des Sel* 25:1–6. doi:[10.1093/protein/gzr053](https://doi.org/10.1093/protein/gzr053)
204. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z (2001) Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. *Prostate* 47:21–28. doi:[10.1002/pros.1043](https://doi.org/10.1002/pros.1043)
205. Gadadhar S, Karande AA (2013) Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway. *PLoS One* 8:e58304. doi:[10.1371/journal.pone.0058304](https://doi.org/10.1371/journal.pone.0058304)
206. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, Barderas R, Canamero M, Ferreira S, Rosenblum MG, Casal JI (2008) Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. *Mol Cancer Ther* 7:862–873. doi:[10.1158/1535-7163.MCT-07-0394](https://doi.org/10.1158/1535-7163.MCT-07-0394)
207. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M (2002) Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. *Prostate* 53:9–23. doi:[10.1002/pros.10117](https://doi.org/10.1002/pros.10117)

208. Gilabert-Oriol R, Thakur M, von Mallinckrodt B, Hug T, Wiesner B, Eichhorst J, Melzig MF, Fuchs H, Weng A (2013) Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. *Mol Pharm* 10:4347–4357. doi:[10.1021/mp400444q](https://doi.org/10.1021/mp400444q)
209. Wei BR, Ghetie MA, Vitetta ES (2000) The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. *Clin Cancer Res* 6:631–642, PMID: 10690549
210. Gillies SD, Young D, Lo KM, Roberts S (1993) Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. *Bioconjug Chem* 4:230–235. doi:[10.1021/bc00021a008](https://doi.org/10.1021/bc00021a008)
211. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. *Nat Rev Drug Discov* 5:147–159. doi:[10.1038/nrd1957](https://doi.org/10.1038/nrd1957)
212. Manusama ER, Nooijen PT, Ten Hagen TL, Van Der Veen AH, De Vries MW, De Wilt JH, Van Ijken MG, Marquet RL, Eggermont AM (1998) Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. *Semin Surg Oncol* 14:232–237. doi:[10.1002/\(SICI\)1098-2388\(199804/05\)14:3<232::AID-SSU7>3.0.CO;2-9](https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9)
213. Cohen J (1995) IL-12 deaths: explanation and a puzzle. *Science* 270:908. doi:[10.1126/science.270.5238.908a](https://doi.org/10.1126/science.270.5238.908a)
214. Mattijssen V, De Mulder PH, De Graeff A, Hupperets PS, Joosten F, Ruiter DJ, Bier H, Palmer PA, Van den Broek P (1994) Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. *Ann Oncol* 5:957–960, PMID 7696170
215. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *J Clin Oncol* 10:52–60, PMID: 1727926
216. Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 6(Suppl 1):S11–S14, PMID: 10685652
217. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. *J Exp Med* 183:2361–2366, PMID: 8642346
218. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. *Nat Biotechnol* 20:264–269. doi:[10.1038/nbt0302-264](https://doi.org/10.1038/nbt0302-264)
219. List T, Neri D (2013) Immunocytokines: a review of molecules in clinical development for cancer therapy. *Clin Pharmacol* 5:29–45. doi:[10.2147/CPAA.S49231](https://doi.org/10.2147/CPAA.S49231)
220. Schrama D, Xiang R, Eggert AO, Andersen MH, Pedersen Ls LO, Kampgen E, Schumacher TN, Reisfeld RR, Becker JC (2004) Shift from systemic to site-specific memory by tumor-targeted IL-2. *J Immunol* 172:5843–5850, PMID: 15128763
221. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. *Blood* 113:2275–2283. doi:[10.1182/blood-2008-05-160747](https://doi.org/10.1182/blood-2008-05-160747)
222. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. *J Invest Dermatol* 133:751–758. doi:[10.1038/jid.2012.376](https://doi.org/10.1038/jid.2012.376)
223. Bauer J, Namineni S, Reisinger F, Zoller J, Yuan D, Heikenwalder M (2012) Lymphotoxin, NF- κ B, and cancer: the dark side of cytokines. *Dig Dis* 30:453–468. doi:[10.1159/000341690](https://doi.org/10.1159/000341690)
224. Huang X, Ye D, Thorpe PE (2011) Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. *Vaccine* 29:4785–4793. doi:[10.1016/j.vaccine.2011.04.082](https://doi.org/10.1016/j.vaccine.2011.04.082)
225. Ziebarth AJ, Felder MA, Harter J, Connor JP (2012) Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. *Cancer Immunol Immunother* 61:1149–1153

226. Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, Kaspar M, Trachsel E, Kosmehl H, Bani MR, Neri D, Giavazzi R (2012) Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. *Cancer Res* 72:1814–1824. doi:[10.1158/0008-5472.CAN-11-1919](https://doi.org/10.1158/0008-5472.CAN-11-1919)
227. Pedretti M, Verpelli C, Marling J, Bertani G, Sala C, Neri D, Bello L (2010) Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. *Br J Cancer* 103:827–836. doi:[10.1038/sj.bjc.6605832](https://doi.org/10.1038/sj.bjc.6605832)
228. Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D (2010) The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. *J Urol* 184:2540–2548. doi:[10.1016/j.juro.2010.07.030](https://doi.org/10.1016/j.juro.2010.07.030)
229. Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM (2009) Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. *Clin Cancer Res* 15:5923–5930
230. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD (2001) Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. *Clin Cancer Res* 7:2862–2869, PMID: 11555604
231. Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmievich AL, Mahvi DM, Gillies SD, Sondel PM (2009) Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. *Clin Cancer Res* 15:4875–4884. doi:[10.1158/1078-0432.CCR-09-0110](https://doi.org/10.1158/1078-0432.CCR-09-0110)
232. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D (2011) Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. *J Biotechnol* 154:84–92. doi:[10.1016/j.jbiotec.2011.04.003](https://doi.org/10.1016/j.jbiotec.2011.04.003)
233. Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW (2014) The immunocytokine NHS-IL12 as a potential cancer therapeutic. *Oncotarget* 5:1869–1884, PMID: 24681847
234. Kim H, Gao W, Ho M (2013) Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. *PLoS One* 8:e81919. doi:[10.1371/journal.pone.0081919](https://doi.org/10.1371/journal.pone.0081919)
235. Gillesen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR, Liedert B, Kramer D, Laurent J, Speiser DE, Stupp R (2013) A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. *Eur J Cancer* 49:35–44. doi:[10.1016/j.ejca.2012.07.015](https://doi.org/10.1016/j.ejca.2012.07.015)
236. Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. *Cancer Res* 67:4940–4948. doi:[10.1158/0008-5472.CAN-07-0283](https://doi.org/10.1158/0008-5472.CAN-07-0283)
237. Liu D, Chang CH, Rossi EA, Cardillo TM, Goldenberg DM (2013) Interferon-lambda1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells. *PLoS One* 8:e63940. doi:[10.1371/journal.pone.0063940](https://doi.org/10.1371/journal.pone.0063940)
238. Chen P, Nogusa S, Thapa RJ, Shaller C, Simmons H, Peri S, Adams GP, Balachandran S (2013) Anti-CD70 immunocytokines for exploitation of interferon-gamma-induced RIP1-dependent necrosis in renal cell carcinoma. *PLoS One* 8:e61446. doi:[10.1371/journal.pone.0061446](https://doi.org/10.1371/journal.pone.0061446)
239. Lyu MA, Kurzrock R, Rosenblum MG (2008) The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. *Biochem Pharmacol* 75:836–846. doi:[10.1016/j.bcp.2007.10.013](https://doi.org/10.1016/j.bcp.2007.10.013)
240. Bagshawe KD (2006) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. *Expert Rev Anticancer Ther* 6:1421–1431. doi:[10.1586/14737140.6.10.1421](https://doi.org/10.1586/14737140.6.10.1421)
241. Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW, Roffler SR (1999) Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. *Br J Cancer* 79:1378–1385. doi:[10.1038/sj.bjc.6690221](https://doi.org/10.1038/sj.bjc.6690221)
242. Sharma SK (2013) Antibody-directed enzyme prodrug therapy (ADEPT). In: Schmidt SR (ed) *Fusion proteins technologies for biopharmaceuticals*. Wiley, New Jersey, pp 354–363

243. Begent RH, Bagshawe KD, Green AJ, Searle F (1987) The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma. *Br J Cancer* 55:657–660. doi:[10.1038/bjc.1987.134](https://doi.org/10.1038/bjc.1987.134)
244. Bagshawe KD (2012) Antibody-directed enzyme prodrug therapy (ADEPT) – basic principles and its practice so far. In: Kratz F, Senter P, Steinhagen H (eds) *Drug delivery in oncology*. Wiley, Germany, pp 169–186
245. Baker M, Carr F (2010) Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. *Curr Drug Saf* 5:308–313. doi:[10.2174/157488610792246000](https://doi.org/10.2174/157488610792246000)
246. Holgate RG, Baker MP (2009) Circumventing immunogenicity in the development of therapeutic antibodies. *IDrugs* 12:233–237, PMID: 19350467
247. Smith GK, Banks S, Blumenkopf TA, Cory M, Humphreys J, Laethem RM, Miller J, Moxham CP, Mullin R, Ray PH, Walton LM, Wolfe LA 3rd (1997) Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. *J Biol Chem* 272:15804–15816, PMID: 9188478
248. Syrigos KN, Rowlinson-Busza G, Epenetos AA (1998) In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. *Int J Cancer* 78:712–719. doi:[10.1002/\(SICI\)1097-0215\(19981209\)78:6<712::AID-IJC8>3.0.CO;2-D](https://doi.org/10.1002/(SICI)1097-0215(19981209)78:6<712::AID-IJC8>3.0.CO;2-D)
249. Chen KC, Wu SY, Leu YL, Prijovich ZM, Chen BM, Wang HE, Cheng TL, Roffler SR (2011) A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. *Bioconjug Chem* 22:938–948. doi:[10.1021/bc1005784](https://doi.org/10.1021/bc1005784)
250. Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E (2006) Characterization of a CC49-based single-chain fragment- β -lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). *Bioconjug Chem* 17:410–418. doi:[10.1021/bc0503521](https://doi.org/10.1021/bc0503521)
251. Wang H, Shi PJ, Wu MF, Li N, Zhou XL, Fan FY (2010) Construction, expression and functional characterization of the beta-lactamase with alphav integrin ligands. *Protein Pept Lett* 17:1562–1565. doi:[10.2174/0929866511009011562](https://doi.org/10.2174/0929866511009011562)
252. Hao XK, Liu JY, Yue QH, Wu GJ, Bai YJ, Yin Y (2006) In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. *Prostate* 66:858–866. doi:[10.1002/pros.20402](https://doi.org/10.1002/pros.20402)
253. Deckert PM, Bornmann WG, Ritter G, Williams C Jr, Franke J, Keilholz U, Thiel E, Old LJ, Bertino JR, Welt S (2004) Specific tumour localisation of a huA33 antibody–carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. *Int J Oncol* 24:1289–1295, PMID: 15067353
254. Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF (1994) Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. *Cancer* 73:1114–1120, PMID: 8306255
255. Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D (2001) Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. *Br J Cancer* 84:1671–1676. doi:[10.1054/bjoc.2001.1843](https://doi.org/10.1054/bjoc.2001.1843)
256. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. *Cancer Res* 59:3998–4003, PMID: 10463598
257. Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, Chester KA (2004) Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). *Br J Cancer* 90:2402–2410. doi:[10.1038/sj.bjc.6601888](https://doi.org/10.1038/sj.bjc.6601888)
258. Park JI, Cao L, Platt VM, Huang Z, Stull RA, Dy EE, Sperinde JJ, Yokoyama JS, Szoka FC (2009) Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase. *Mol Pharm* 6:801–812. doi:[10.1021/mp800013c](https://doi.org/10.1021/mp800013c)

259. Coelho V, Darnedde J, Petrusch U, Panjideh H, Fuchs H, Menzel C, Dubel S, Keilholz U, Thiel E, Deckert PM (2007) Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. *Int J Oncol* 31:951–957. PMID: 17786329
260. Biela BH, Khawli LA, Hu P, Epstein AL (2003) Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). *Cancer Biother Radiopharm* 18:339–353. doi:[10.1089/108497803322285099](https://doi.org/10.1089/108497803322285099)
261. Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K (1998) Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. *J Med Chem* 41:3572–3581. doi:[10.1021/jm9705891](https://doi.org/10.1021/jm9705891)
262. Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, Vd Meulen-Muileman IH, Pinedo HM, Boven E (1998) Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. *Blood* 92:184–190. PMID 9639515
263. Afshar S, Asai T, Morrison SL (2009) Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. *Mol Cancer Ther* 8:185–193. doi:[10.1158/1535-7163.MCT-08-0652](https://doi.org/10.1158/1535-7163.MCT-08-0652)
264. Heinis C, Alessi P, Neri D (2004) Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. *Biochemistry* 43:6293–6303. doi:[10.1021/bi0361160](https://doi.org/10.1021/bi0361160)
265. Knox RJ, Friedlos F, Boland MP (1993) The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). *Cancer Metastasis Rev* 12:195–212. doi:[10.1007/bf00689810](https://doi.org/10.1007/bf00689810)
266. Lu JY, Lowe DA, Kennedy MD, Low PS (1999) Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. *J Drug Target* 7:43–53. doi:[10.3109/10611869909085491](https://doi.org/10.3109/10611869909085491)
267. Padiolleau-Lefevre S, Naya RB, Shahsavarian MA, Friboulet A, Avalle B (2014) Catalytic antibodies and their applications in biotechnology: state of the art. *Biotechnol Lett* 36(7):1369–79. doi:[10.1007/s10529-014-1503-8](https://doi.org/10.1007/s10529-014-1503-8)
268. Abraham S, Guo F, Li LS, Rader C, Liu C, Barbas CF 3rd, Lerner RA, Sinha SC (2007) Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. *Proc Natl Acad Sci USA* 104:5584–5589. doi:[10.1073/pnas.0700223104](https://doi.org/10.1073/pnas.0700223104)
269. Zawilska JB, Wojcieszak J, Olejniczak AB (2013) Prodrugs: a challenge for the drug development. *Pharmacol Rep* 65:1–14. doi:[10.1016/S1734-1140\(13\)70959-9](https://doi.org/10.1016/S1734-1140(13)70959-9)
270. Jain S, Kumar D, Swarnakar NK, Thanki K (2012) Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. *Biomaterials* 33:6758–6768. doi:[10.1016/j.biomaterials.2012.05.026](https://doi.org/10.1016/j.biomaterials.2012.05.026)
271. Sapra P, Shor B (2013) Monoclonal antibody-based therapies in cancer: advances and challenges. *Pharmacol Ther* 138:452–469. doi:[10.1016/j.pharmthera.2013.03.004](https://doi.org/10.1016/j.pharmthera.2013.03.004)
272. Iden DL, Allen TM (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. *Biochim Biophys Acta* 1513:207–216. doi:[10.1016/S0005-2736\(01\)00357-1](https://doi.org/10.1016/S0005-2736(01)00357-1)
273. Ishida T, Iden DL, Allen TM (1999) A combinatorial approach to producing sterically stabilized (stealth) immunoliposomal drugs. *FEBS Lett* 460:129–133. doi:[10.1016/S0014-5793\(99\)01320-4](https://doi.org/10.1016/S0014-5793(99)01320-4)
274. Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. *Expert Opin Drug Deliv* 5:189–204. doi:[10.1517/17425247.5.2.189](https://doi.org/10.1517/17425247.5.2.189)
275. Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. *Cancer Res* 62:7190–7194. PMID: 12499256
276. Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G (2002) Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. *J Biol Chem* 277:27135–27143. doi:[10.1074/jbc.M200429200](https://doi.org/10.1074/jbc.M200429200)

277. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov* 4:145–160. doi:[10.1038/nrd1632](https://doi.org/10.1038/nrd1632)
278. Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H (2013) Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. *Biomaterials* 34:10084–10098. doi:[10.1016/j.biomaterials.2013.08.088](https://doi.org/10.1016/j.biomaterials.2013.08.088)
279. Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, Li B, Zhang D, Qian W, Meng Y (2011) The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. *Biomaterials* 32:3459–3470. doi:[10.1016/j.biomaterials.2011.01.034](https://doi.org/10.1016/j.biomaterials.2011.01.034)
280. Deng L, Zhang Y, Ma L, Jing X, Ke X, Lian J, Zhao Q, Yan B, Zhang J, Yao J, Chen J (2013) Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells. *Int J Nanomedicine* 8:3271–3283. doi:[10.2147/IJN.S47597](https://doi.org/10.2147/IJN.S47597)
281. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB (2010) Development of a highly stable and targetable nanoliposomal formulation of topotecan. *J Control Release* 141:13–21. doi:[10.1016/j.jconrel.2009.08.006](https://doi.org/10.1016/j.jconrel.2009.08.006)
282. Nishikawa K, Asai T, Shigematsu H, Shimizu K, Kato H, Asano Y, Takashima S, Mekada E, Oku N, Minamino T (2012) Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. *J Control Release* 160:274–280. doi:[10.1016/j.jconrel.2011.10.010](https://doi.org/10.1016/j.jconrel.2011.10.010)
283. Apte A, Koren E, Koshkaryev A, Torchilin VP (2014) Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. *Cancer Biol Ther* 15:69–80. doi:[10.4161/cbt.26609](https://doi.org/10.4161/cbt.26609)
284. Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. *Clin Cancer Res* 18:454–464. doi:[10.1158/1078-0432.CCR-11-1102](https://doi.org/10.1158/1078-0432.CCR-11-1102)
285. Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R, Wang MH (2011) Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. *Mol Pharm* 8:2310–2319. doi:[10.1021/mp200193u](https://doi.org/10.1021/mp200193u)
286. Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP, Wang MH (2011) Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. *Cancer Chemother Pharmacol* 67:1073–1083. doi:[10.1007/s00280-010-1408-8](https://doi.org/10.1007/s00280-010-1408-8)
287. Mortensen JH, Jeppesen M, Pilgaard L, Agger R, Duroux M, Zachar V, Moos T (2013) Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. *J Drug Deliv* 2013:209205. doi:[10.1155/2013/209205](https://doi.org/10.1155/2013/209205)
288. Lehtinen J, Raki M, Bergstrom KA, Uutela P, Lehtinen K, Hiltunen A, Pikkarainen J, Liang H, Pitkanen S, Maatta AM, Ketola RA, Yliperttula M, Wirth T, Urtti A (2012) Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. *PLoS One* 7:e41410. doi:[10.1371/journal.pone.0041410](https://doi.org/10.1371/journal.pone.0041410)
289. Hantel C, Lewrick F, Schneider S, Zwermann O, Perren A, Reincke M, Suss R, Beuschlein F (2010) Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. *J Clin Endocrinol Metab* 95:943–952. doi:[10.1210/jc.2009-1980](https://doi.org/10.1210/jc.2009-1980)
290. Koren E, Apte A, Jani A, Torchilin VP (2012) Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. *J Control Release* 160:264–273. doi:[10.1016/j.jconrel.2011.12.002](https://doi.org/10.1016/j.jconrel.2011.12.002)

291. Kullberg M, Mann K, Anchordoquy TJ (2012) Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. *Mol Pharm* 9:2000–2008. doi:[10.1021/mp300049n](https://doi.org/10.1021/mp300049n)
292. Catania A, Barrajon-Catalan E, Nicolosi S, Cicirata F, Micol V (2013) Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. *Breast Cancer Res Treat* 141:55–65. doi:[10.1007/s10549-013-2667-y](https://doi.org/10.1007/s10549-013-2667-y)
293. Yamamoto Y, Yoshida M, Sato M, Sato K, Kikuchi S, Sugishita H, Kuwabara J, Matsuno Y, Kojima Y, Morimoto M, Horiuchi A, Watanabe Y (2011) Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. *Int J Oncol* 38:33–39, PMID: 21109923
294. Srivastava A, O'Connor IB, Pandit A, Gerard Wall J (2014) Polymer-antibody fragment conjugates for biomedical applications. *Prog Polym Sci* 39:308–329. doi:[10.1016/j.progpolymsci.2013.09.003](https://doi.org/10.1016/j.progpolymsci.2013.09.003)
295. Hagemeyer CE, von Zur MC, von Elverfeldt D, Peter K (2009) Single-chain antibodies as diagnostic tools and therapeutic agents. *Thromb Haemost* 101:1012–1019, PMID: 19492141
296. Hu X, Spada S, White S, Hudson S, Magner E, Wall JG (2006) Adsorption and activity of a domoic acid binding antibody fragment on mesoporous silicates. *J Phys Chem B* 110:18703–18709. doi:[10.1021/jp062423e](https://doi.org/10.1021/jp062423e)
297. Albrecht H, Denardo GL, Denardo SJ (2006) Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. *J Immunol Methods* 310:100–116. doi:[10.1016/j.jim.2005.12.012](https://doi.org/10.1016/j.jim.2005.12.012)
298. Weissner NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. *Biotechnol Adv* 27:502–520. doi:[10.1016/j.biotechadv.2009.04.004](https://doi.org/10.1016/j.biotechadv.2009.04.004)
299. Yang K, Basu A, Wang M, Chintala R, Hsieh MC, Liu S, Hua J, Zhang Z, Zhou J, Li M, Phyu H, Petti G, Mendez M, Janjua H, Peng P, Longley C, Borowski V, Mehlig M, Filpula D (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. *Protein Eng* 16:761–770. doi:[10.1093/protein/gzg093](https://doi.org/10.1093/protein/gzg093)
300. Kim SH, Lee YS, Hwang SY, Bae GW, Nho K, Kang SW, Kwak YG, Moon CS, Han YS, Kim TY, Kho WG (2007) Effects of PEGylated scFv antibodies against Plasmodium vivax Duffy binding protein on the biological activity and stability in vitro. *J Microbiol Biotechnol* 17:1670–1674, PMID: 18156783
301. Kitamura K, Takahashi T, Takashina K, Yamaguchi T, Noguchi A, Tsurumi H, Toyokuni T, Hakomori S (1990) Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. *Biochem Biophys Res Commun* 171:1387–1394. doi:[10.1016/0006-291X\(90\)90839-F](https://doi.org/10.1016/0006-291X(90)90839-F)
302. Delgado C, Pedley RB, Herraiz A, Boden R, Boden JA, Keep PA, Chester KA, Fisher D, Begent RH, Francis GE (1996) Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. *Br J Cancer* 73:175–182. doi:[10.1038/bjc.1996.32](https://doi.org/10.1038/bjc.1996.32)
303. Casey J, Pedley R, King D, Boden R, Chapman A, Yarranton G, Begent R (1999) Improved tumour targeting of di-Fab' fragments modified with polyethylene glycol. *Tumor Target* 4:235–244, <http://discovery.ucl.ac.uk/333098/>
304. Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE (2006) Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. *Bioconjug Chem* 17:68–76. doi:[10.1021/bc0502614](https://doi.org/10.1021/bc0502614)
305. Lu ZR, Kopeckova P, Kopecek J (1999) Polymerizable Fab' antibody fragments for targeting of anticancer drugs. *Nat Biotechnol* 17:1101–1104. doi:[10.1038/15085](https://doi.org/10.1038/15085)
306. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julian PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ, Cancer Research Campaign Phase IICTc (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. *J Clin Oncol* 20:1668–1676, PMID: 11896118

307. Hovorka O, St'astny M, Etrych T, Subr V, Strohalm J, Ulbrich K, Rihova B (2002) Differences in the intracellular fate of free and polymer-bound doxorubicin. *J Control Release* 80:101–117. doi:[10.1016/S0168-3659\(02\)00016-0](https://doi.org/10.1016/S0168-3659(02)00016-0)
308. Satchi R, Connors TA, Duncan R (2001) PDEPT: polymer-directed enzyme prodrug therapy. I. HPMa copolymer-cathepsin B and PK1 as a model combination. *Br J Cancer* 85:1070–1076
309. Etrych T, Strohalm J, Kovar L, Kabesova M, Rihova B, Ulbrich K (2009) HPMa copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity. *J Control Release* 140:18–26
310. Gao J, Xia Y, Chen H, Yu Y, Song J, Li W, Qian W, Wang H, Dai J, Guo Y (2014) Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. *Nanomedicine (Lond)* 9:279–293. doi:[10.2217/nmm.13.20](https://doi.org/10.2217/nmm.13.20)
311. Khaw BA, Gada KS, Patil V, Panwar R, Mandapati S, Hatefi A, Majewski S, Weisenberger A (2014) Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts : targeted polymer drug conjugates for cancer diagnosis and therapy. *Eur J Nucl Med Mol Imaging* 41(8):1603–1616. doi:[10.1007/s00259-014-2738-2](https://doi.org/10.1007/s00259-014-2738-2)
312. Liu J, Kopeckova P, Buhler P, Wolf P, Pan H, Bauer H, Elsasser-Beile U, Kopecek J (2009) Biorecognition and subcellular trafficking of HPMa copolymer-anti-PSMA antibody conjugates by prostate cancer cells. *Mol Pharm* 6:959–970. doi:[10.1021/mp8002682](https://doi.org/10.1021/mp8002682)
313. Satchi-Fainaro R, Wrasidlo W, Lode HN, Shabat D (2002) Synthesis and characterization of a catalytic antibody-HPMa copolymer-conjugate as a tool for tumor selective prodrug activation. *Bioorg Med Chem* 10:3023–3029. doi:[10.1016/s0968-0896\(02\)00156-6](https://doi.org/10.1016/s0968-0896(02)00156-6)
314. Berguig GY, Convertine AJ, Shi J, Palanca-Wessels MC, Duvall CL, Pun SH, Press OW, Stayton PS (2012) Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. *Mol Pharm* 9:3506–3514. doi:[10.1021/mp300338s](https://doi.org/10.1021/mp300338s)
315. Tappertzshofen K, Metz VV, Hubo M, Barz M, Postina R, Jonuleit H, Zentel R (2013) Synthesis of maleimide-functionalized HPMa-copolymers and in vitro characterization of the aRAGE- and human immunoglobulin (huIgG)-polymer conjugates. *Macromol Biosci* 13:203–214. doi:[10.1002/mabi.201200344](https://doi.org/10.1002/mabi.201200344)
316. Rihova B, Kopeckova P, Strohalm J, Rossmann P, Vetvicka V, Kopecek J (1988) Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMa copolymers and targeting antibody. *Clin Immunol Immunopathol* 46:100–114. doi:[10.1016/0090-1229\(88\)90010-4](https://doi.org/10.1016/0090-1229(88)90010-4)
317. Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopeckova P, Kissel T, Kopecek J (2003) Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. *Bioconjug Chem* 14:989–996. doi:[10.1021/bc0340767](https://doi.org/10.1021/bc0340767)
318. Pechar M, Ulbrich K, Jelínková M, Říhová B (2003) Conjugates of antibody-targeted PEG multiblock polymers with doxorubicin in cancer therapy. *Macromol Biosci* 3:364–372. doi:[10.1002/mabi.200350004](https://doi.org/10.1002/mabi.200350004)
319. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP (2013) Nanopreparations to overcome multidrug resistance in cancer. *Adv Drug Deliv Rev* 65:1748–1762. doi:[10.1016/j.addr.2013.08.004](https://doi.org/10.1016/j.addr.2013.08.004)
320. Kirtane AR, Kalscheuer SM, Panyam J (2013) Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. *Adv Drug Deliv Rev* 65:1731–1747. doi:[10.1016/j.addr.2013.09.001](https://doi.org/10.1016/j.addr.2013.09.001)
321. Yan Y, Bjornmalm M, Caruso F (2013) Particle carriers for combating multidrug-resistant cancer. *ACS Nano* 7:9512–9517. doi:[10.1021/nn405632s](https://doi.org/10.1021/nn405632s)
322. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Adv Drug Deliv Rev* 66C:2–25. doi:[10.1016/j.addr.2013.11.009](https://doi.org/10.1016/j.addr.2013.11.009)

Targeted Drug Delivery : Concepts and Design

Devarajan, P.V.; Jain, S. (Eds.)

2015, XVIII, 790 p. 125 illus., 103 illus. in color.,

Hardcover

ISBN: 978-3-319-11354-8